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Abstract 
 
The adaptor subunit of phosphatidylinositol 3'-kinases (PI3K), p85, is involved in many 
different biological processes.  Recent studies have shown that one of these functions is to 
serve as a GTPase activating protein (GAP) towards Rab5, a small monomeric G-protein.  
Rab5, like other G-proteins, can bind to either GDP or GTP in vivo, assuming its inactive and 
active form, respectively.  The p85 protein has been shown to associate with both the 
nucleotide-bound and nucleotide-free states of Rab5.  It has also been shown that p85 
associates with activated, phosphorylated platelet-derived growth factor receptors (PDGFRs) 
via its two SH2 domains, and that upon binding there is a conformational change in the p85 
protein which leads to a derepression of p110 kinase activity.  The purpose of this study was to 
analyze if binding of the activated PDGFR peptides to p85 affects its Rab5GAP activity, as 
well as to measure the binding affinity of p85 towards Rab5 in each of its nucleotide-bound 
states.  GAP assays were performed to measure the effect that peptide analogs of both the 
activated and inactivated PDGFR had on p85 Rab5GAP activity, while the binding affinity of 
p85 towards Rab5 was measured using surface plasmon resonance.  The results of this study 
suggest that PDGFR peptides have no significant effect on p85 Rab5GAP activity.  
Furthermore, p85 appears to have a higher magnitude of binding to nucleotide-associated Rab5 
proteins, than nucleotide-free Rab5 proteins.  It also appears that p85 forms more stable 
complexes with Rab5-GTP than with Rab5-GDP.  These results further support previous 
studies that show p85 to be an important regulator of Rab5-mediated endosomal fusion and 
show that this activity is not regulated by binding to the activated PDGFR itself.  
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1.0 Introduction 
 
1.1 Signal Transduction Pathways 
Signal transduction pathways are the primary means used by cells to respond to external 
stimuli and consist of numerous signalling molecules ranging from lipids to nucleic acids.  
These pathways allow cells to respond to a wide variety of signals, including hormones, ions, 
and gases (Schuller, 1991).  Signal transduction pathways start at the plasma membrane, the 
interface between the cell and the outside world.  On the membrane are a number of specialized 
receptors which respond to different extracellular stimuli.  These receptors then transduce the 
information gathered from these external stimuli into the cell where they elicit a number of 
biochemical reactions to yield the appropriate cellular response. 
In order to produce the strongest possible response to even a minimum stimulus, signal 
transduction pathways are typically amplified. This allows a small number of activated 
receptors to stimulate a sufficiently strong reaction from the cell.  To this end, cells have 
evolved a means of having a relatively small number of signalling pathways activated by a 
wide variety of receptors.  These form a complex system which can provide a number of 
unique signals from a limited number of signalling molecules (Citri and Yarden, 2006). 
In order to yield such a wide range of responses from such a limited pool of signalling 
molecules, a means of differentiating external signals had to be developed in order to keep the 
cell responses clear.   To this end, all cells have developed techniques to modify and sequester 
proteins in space and/or time as a means of regulating the cellular response.  One of the most 
powerful methods cells use to specifically activate cell signalling molecules to specific tasks is 
through post-translational modifications.  Post-translational modification occurs when proteins 
are chemically modified after the protein is translated from RNA. These modifications can alter 
the chemical properties, cellular localization, biological activity, or physical structure of the 
protein in question (Olsen et al., 2006; Yang and Seto, 2008).  
One example of a post-translational modification used to regulate protein molecules is 
the phosphorylation amino acid residues by kinase enzymes.  These phosphorylations can also 
be removed through the actions of phosphatase enzymes.  (Burnett and Kennedy, 1954; 
Cozzone, 1988).  These phosphorylations and dephosphorylations can either activate or 
deactivate the proteins in question or alter other properties such as binding functions or 
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localization (Olsen et al., 2006).  Proteins are typically phosphorylated on one or more tyrosine, 
serine, or threonine residues.  These phosphorylated residues can serve a number of roles 
including forming binding sites for specific protein binding domains.  An example of this is the 
Src homology 2 (SH2) domain which binds to phosphorylated tyrosine and three to six 
additional amino acids adjacent to the phosphotyrosine residue (Bradshaw and Waksman, 
2002; Grucza et al., 1999). 
 
1.2 Receptor Tyrosine Kinases 
 Receptor tyrosine kinases (RTKs) are integral membrane cell surface receptors which 
are activated by extracellular signals.  There are several subfamilies of RTKs which share many 
conserved domains, though with different affinities to different ligands (Zwick et al., 2001).  
What makes RTKs unique among cell surface receptors is that they, as the name suggests, have 
intrinsic protein tyrosine kinase activity when activated.  All RTKs have a similar domain 
structure consisting of an extracellular ligand binding domain, a single α-helical 
transmembrane domain, and a cytoplasmic domain containing the intrinsic tyrosine kinase 
domain with enzymatic activity as well as phosphorylation sites  (Ogiso et al., 2002; Pawson 
and Scott, 2005; Schlessinger, 2000) (Fig. 1.1).  When a RTK binds its ligand, it undergoes a 
conformational change which allows it to dimerize (Biarc et al., 2011; Garrett et al., 1998; 
Ogiso et al., 2002).  Once dimerized, the receptor undergoes an additional conformational 
change which induces the cross-phosphorylation (also known as trans-autophosphorylation) of 
the PDGFR monomers in their cytosolic domain (Ferguson, 2008).  These phosphorylated 
tyrosine residues then serve as docking sites for proteins which are involved in further 
downstream signalling events. 
 There are many different types of RTKs expressed in human cells, two of which being 
the epidermal growth factor (EGF) receptor (EGFR) and the platelet-derived growth factor 
(PDGF) receptor (PDGFR) (Alvarez et al., 2006; Robinson et al., 2000).  One of the signalling 
pathways that are activated by these receptors is the phosphatidylinositol 3'-kinase (PI3K)/Akt 
signalling pathway.  This pathway is known to promote cell division and survival, as well as 
cell motility and invasion in cancer cells (Chin and Toker, 2009) (Fig. 1.2).  The 
phosphorylated receptor recruits the PI3K complex via two of its phosphorylated tyrosine 
residues.  Once bound to the activated receptor, PI3K can then phosphorylate phosphatidylino- 
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Figure 1.1 – Receptor tyrosine kinase activation.  Receptor tyrosine kinases (RTKs) 
generally consist of an extracellular ligand binding domain, a transmembrane domain, and an 
intracellular tyrosine kinase domain which contains multiple phosphorylation sites.  Upon 
binding their corresponding ligand to their extracellular binding domain, RTKs such as the 
platelet-derived growth factor receptor dimerize.  This allows for autophosphorylation of the 
intracellular domain of the receptor.  
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Figure 1.2 – PDGFR activates the PI3K/Akt signalling pathway, promoting cell division, 
survival, and motility.  Upon PDGF stimulation, the PDGFR subunits dimerize which leads to 
autophosphorylation of tyrosine residues on the intracellular domains of the PDGFR subunits.  
The PI3K enzyme complex is recruited to the PDGFR via the SH2 domains in the p85 
regulatory subunit binding to the phosphorylated tyrosine residues.  When localized to the 
plasma membrane, p110 can phosphorylate PI4,5P2 to produce PI3,4,5P3, recruiting the 
serine/threonine kinase Akt which is involved in downstream signalling.  PI3,4,5P3 can then be 
deactivated by the phosphatase enzyme PTEN which is itself activated by dephosphorylation 
by an unknown phosphatase.  This exposes positively charged residues on PTEN which allow it 
to associate with the plasma membrane.  PTEN is then deactivated by phosphorylation by 
casein kinase II (Fruman et al., 1998; Ueki et al., 2002). 
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sitol 4,5-bisphosphate (PI4,5P2) to  phosphatidylinositol 3,4,5-trisphosphate (PI3,4,5P3) which 
functions as a second messenger for 3-phosphoinositide dependent protein kinase-1 (PDPK1).  
This enzyme proceeds to phosphorylates the serine/threonine kinase Akt, which then activates a 
number of downstream proteins which promote anti-apoptotic signals (Fruman et al., 1998; 
Ueki et al., 2002). 
 
1.3 Phosphatidylinositol 3'-kinase (PI3K) 
 PI3K belongs to an important enzyme superfamily which plays pivotal roles in 
metabolic and mitogenic signalling pathways.  PI3K enzymes are lipid kinases and fall into 
three distinct classes, labelled Class I to III.  Class I PI3Ks are heterodimers consisting of a 
catalytic subunit (p110) and a regulatory or adaptor subunit (p85).  Class I PI3K can be further 
divided into Class IA and IB by sequence similarity and are the only PI3K enzymes activated in 
response to RTK activation (Carpenter and Cantley, 1996).   
The catalytic subunit of Class IA PI3K enzymes consist of one of three isoforms of 
p110:  p110 , , and δ (Fig. 1.3A).  Of these isoforms, p110  and p110  are expressed in all 
cells, while p110δ is primarily expressed in leukocytes (Arcaro et al., 2000; Fruman et al., 
1998; Ueki et al., 2002).  Of these three isoforms p110  and δ exhibit more primary sequence 
similarity towards each other than to p110 , though all three share a similar domain structure 
(Vanhaesebroeck and Waterfield, 1999) (Fig. 1.3A).  All three isoforms contain an N-terminal 
adaptor protein binding domain (ABD; i.e., p85 binding domain), followed by a Ras-binding 
domain (RBD), a protein kinase-C-homology domain 2 (C2 domain) responsible for lipid 
binding, a helical domain, and a kinase domain (Zhao and Vogt, 2008). 
Like p110, the regulatory or adaptor subunit of Class IA PI3K, p85, also has different 
isoforms (Fig. 1.3B).  These consist of p85  as well as the splice variants p55  and p50 , (all 
encoded by the Pik3r1 gene), the p85  (encoded by the Pik3r2 gene), and the p55γ (encoded by 
the Pik3r3 gene) (Fruman et al., 1998; Ueki et al., 2002). The p85 subunit of class IA PI3K 
acts to localize the catalytic subunit p110 to the plasma membrane in response to growth factor 
stimulation and activation of growth factor receptors such as the PDGFR (Engelman et al., 
2006).  When not bound to an activated growth factor receptor, p85 assumes a conformation 
which inhibits the lipid phosphorylation activity of p110, a repression which is relieved 
following binding to an activated RTK (Gearing, 2007; Yu et al., 1998). 
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Figure 1.3 – Domain Structure of PI3K protein components.  A) There are three different 
isoforms of the p110 catalytic subunit of Class IA PI3K: p110 , p110 , and p110δ.  While all 
three have different primary sequences, all three of these isoforms have similar domain 
structures containing an adaptor protein binding domain (ABD), a Ras binding domain (RBD), 
a protein kinase-C-homology 2 (C2) domain, a helical domain, and a catalytic domain.  There 
is 39% similarity between p110  and p110 , and 39% similarity between p110  and p110δ, 
and 56% similarity between p110  and p110δ. B) There are five isoforms of the p85 regulatory 
domain found in Class IA PI3K.  The first three (p85 , p55 , and p50 ) are formed from 
alternative splicing from the Pik3r1 gene, while the others are obtained from the Pik3r2 gene 
(p85 , 57.7% homology to p85 ) or the Pik3r3 gene (p55γ).  The p85 protein contains several 
different domains in various combinations depending on the isoform:  the SH3 binding domain, 
a breakpoint cluster region homology (BH) domain typically flanked by two proline-rich 
regions, a p110 binding domain (also known as the interSH2 or iSH2) which is flanked by two 
SH2 domains.  
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The p85 protein structure includes many protein-protein binding domains allowing it to 
bind to a variety of different partners.  These domains consist of an N-terminal Src homology 3 
(SH3) domain, and a breakpoint cluster region homology (BH) domain which is flanked by two 
proline rich regions.  Following the  second of the proline-rich regions are two SH2 domains, 
between which is the p110 binding domain (Fruman et al., 1998) (Fig. 1.3B).   
SH3 domains bind to a consensus sequence motif of PxxP.  The SH3 domain is a very 
common protein-protein interaction domain, found in a broad range of different protein 
pathways.  It is known to bind with proteins such as focal adhesion kinase and the E3 ubiquitin 
ligase Cbl (Odai et al., 1995).  The N-terminal proline rich regions of p85 are known to form 
dimers between p85 proteins by interacting with SH3 domains on their respective proteins 
(Booker et al., 1993; Guinebault et al., 1995; Harpur et al., 1999; Hunter et al., 1997; Mayer, 
2001).  It is not presently known if one proline-rich region is selected over another for binding. 
The BH domain is also known to self dimerize and has sequence similarity to GTPase 
activating proteins (GAP), discussed later (Chamberlain and Anderson, 2005; Harpur et al., 
1999).  The proline rich regions flanking the BH domain are known to bind to the SH3 domains 
of Src family kinases and to the Abl tyrosine kinase in addition to the SH3 domain of p85 itself 
(Harpur et al., 1999; Kapeller et al., 1994; Pleiman et al., 1994).  The two SH2 domains bind to 
phosphorylated tyrosine sequences pY-X-X-M (pY being phosphotyrosine) in proteins such as 
activated receptor tyrosine kinases and/or adaptor proteins (Piccione et al., 1993; Shoelson et 
al., 1993).  The final domain, located between the two SH2 domains is the p110-binding 
domain, or alternatively the interSH2 (iSH2) domain.  This domain contains two critical 
functions: to bind to the ABD and C2 domains of p110, and to stabilize the resulting 
heterodimer (Fruman, 2010; Miled et al., 2007; Huang et al., 2007).   
In contrast to Class IA PI3K, Class IB PI3K enzymes consist of the p110γ catalytic 
subunit and the p101 adaptor subunit and are activated by the γ subunit of heterotrimeric 
GTP-binding proteins (Arcaro et al., 2000).  All Class I PI3K enzymes have been shown to 
phosphorylate phosphatidylinositol (PI), PI4-phosphate (PI4P), and PI4,5P2 to produce the lipid 
products PI3P, PI3,4P2, and PI3,4,5P3 respectively in vitro.  However, in vivo studies have only 
observed that class I PI3K phosphorylates PI4,5P2 to PI3,4,5P3 (Arcaro et al., 2000; Carpenter 
and Cantley, 1996; Ilic and Roberts, 2010).  Class II PI3K consists of a single catalytic subunit 
with no regulatory subunit, and are distinguished by a carboxy-terminal C2 (CalB) domain 
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(Schu et al., 1993).  There are three isoforms of class II PI3K, named C2 , C2 , and C2γ 
(Carpenter and Cantley, 1996; Fruman et al., 1998).  The Class II PI3K phosphorylates PI or 
PI4P in vitro, though some evidence supports their ability to also phosphorylate PI4,5P2 
(Arcaro et al., 2000; Domin et al., 1997).  Class III PI3Ks are involved in membrane trafficking 
through production of PI3P (Herman and Emr, 1990; Volinia et al., 1995).  Class III PI3K 
enzymes are structurally more similar to class I PI3K than the class II PI3K, since they consist 
of a catalytic (Vps34) and regulatory (Vps15/p150) subunit.  However, like class II PI3K their 
main lipid product is PI3P (Leevers et al., 1999).  
 
1.4 Endocytosis 
 Endocytosis is the process where extracellular material or cell surface receptors are 
internalized into the cell through the formation of vesicles (Marsh and McMahon, 1999).  
There are many different types of endocytosis, ranging from phagocytosis where large 
extracellular particles, such as apoptotic bodies, are taken into the cell, to pinocytosis where 
extracellular fluids are taken into the cell along with any dissolved nutrients therein 
(Mukherjee et al., 1997).  One form of endocytosis, known as receptor-mediated endocytosis, 
is specifically activated when cell-surface receptors are activated and require internalization 
for either deactivation or to transduce their information into the cell.  An example of this is the 
RTK PDGFR, which is internalized into endosomes and trafficked through the endocytic 
pathway (Rosenfeld et al., 1984).  
 There are two main pathways used to internalize activated cell surface receptor 
complexes via receptor-mediated endocytosis: the clathrin-mediated endocytosis pathway, and 
the caveolin-mediated endocytosis pathway (Doherty and McMahon, 2009; Sorkin and von 
Zastrow, 2009).  Clathrin-mediated endocytosis utilizes a protein lattice which coats the inside 
surface of pits made in the plasma membrane (Edeling et al., 2006).  Caveolin-mediated 
endocytosis, on the other hand, utilizes lipid rafts consisting of large concentrations of 
cholesterol and glycosphingolipids known as caveolae which contain the protein caveolin 
(Anderson, 1998; Li et al., 2005; Miaczynska and Zerial, 2002).  Caveolin associates with the 
membrane creating a spiral-like structure.  It is believed that this spiral formation warps the 
plasma membrane into a concave structure, thereby creating an invagination.  These 
invaginations are often used for the uptake of cell surface receptors as well as lipids 
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(Anderson, 1998).  Regardless of the method of endocytosis, endocytic vesicles are 
internalized from the plasma membrane through scission events mediated by the large GTPase 
dynamin, a protein which has its activity upregulated by the p85 adaptor subunit of PI3K 
(Gout et al., 1993). 
 Once internalized, the vesicles, known as early endosomes, are routed through the 
endosomal pathway.  They are small enclosed membrane structures which act as intracellular 
taxis for proteins as they move between different endosomal compartments.  Early/sorting 
endosomes are much larger, semi-permanent structures which act as a warehouse in the cell 
where the vesicle cargos are sorted to other parts of the cell.  The most prominent examples of 
endosome types are early endosomes, early/sorting endosomes, the recycling endosomes, and 
the late endosomes (Miaczynska and Zerial, 2002).  Activated receptor complexes are 
internalized into vesicles which are then trafficked into the early/sorting endosome formed by 
the homotypic fusion of these early endosomal vesicles.  The endocytosed material is then 
sorted from the early/sorting endosome for either degradation (via the lysosome by way of the 
late endosome) or for recycling (via the recycling endosome) back to the plasma membrane 
(Miaczynska and Zerial, 2002) (Fig. 1.4). 
 
1.5 Rab Proteins 
 Rab proteins (or ras gene from rat brain proteins) are members of a family of 
monomeric G proteins which regulate the composition of endosomal domains as well as the 
fusion and fission of endosomes (Touchot et al., 1987).  There are more than 60 Rab proteins 
reported in humans with each one regulating a specific trafficking function in the cell in 
relation to endosomes (Barr and Lambright, 2010; Pereira-Leal and Seabra, 2000; Seabra and 
Wasmeier, 2004; Stenmark and Olkkonen, 2001).  While some Rab proteins are only expressed 
in certain tissues, others such as Rab5 are more broadly expressed in many different tissues 
(Stenmark and Olkkonen, 2001).  Rab proteins typically contain prenyl groups which are 
inserted into membranes when the proteins are activated through an as yet unknown method 
(Stenmark and Olkkonen, 2001).   
A Rab protein is considered to be in its active state when it is GTP-bound, and inactive 
when GDP-bound or lacking an associated guanosine nucleotide. Rab proteins can be ‗turned 
on‘ through the displacement of their associated GDP molecules by guanine nucleotide excha- 
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Figure 1.4 – PDGF-mediated endocytosis and trafficking of the PDGFR is regulated by 
Rab GTPases.  1) Uptake of activated PDGFR complexes from the plasma membrane to 
intracellular vesicles is mediated by endocytosis.  2) Rab5 regulates vesicle fusion events to 
move activated PDGFR complexes to the early/sorting endosome.  3) From the early/sorting 
endosome, PDGFRs can be either recycled to the plasma membrane following deactivation or 
4) targeted into multivesicular bodies (MVBs) for lysosomal degradation. 
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nge factors (GEFs) which facilitate the exchange of a GDP molecule for a GTP molecule.  The 
GTP-bound state moves two distinct regions known as Switch I and Switch II into position 
which allows for effector proteins such as the early endosomal autoantigen 1 (EEA1) to bind to 
the Rab protein  (Pereira-Leal and Seabra, 2000; Seabra and Wasmeier, 2004; Stenmark and 
Olkkonen, 2001; Terzyan et al., 2004) (Fig. 1.5). Rab proteins, like all small monomeric G 
proteins, contain a weak intrinsic GTPase activity which can be enhanced by a GTPase 
activating protein (GAP), to hydrolyze bound GTP to GDP.  There have been many putative 
Rab GAPs identified over the years, with many such proteins containing a Tre-2/Bub2/Cdc16 
(TBC) domain.  However, most GAPs tend to be protein-specific and only a few putative GAPs 
have been matched to their corresponding Rab proteins (Albert et al., 1999; Bernards, 2003; 
Strom et al., 1993). 
When in the inactive, GDP-bound state, Rab proteins are located in the cytoplasm 
bound to a guanosine nucleotide dissociation inhibitor (GDI) protein (Kinchen and 
Ravichandran, 2010; Stenmark and Olkkonen, 2001). GDI proteins mask the prenylation of the 
Rab protein, preventing its insertion into membranes and segregating it to the cytoplasm.  This 
GDI protein can be removed through the actions of a GDI-displacement factor (GDF).  Human 
GDFs are not well characterized, though in yeast Yip proteins are known to fill this role 
(Pfeffer and Aivazian, 2004).  When the GDI is removed, the Rab proteins associate with 
vacuoles and endocytic vesicle membranes.  Once the Rab proteins are membrane-associated, 
GEF proteins can displace the bound GDP to allow GTP binding, activating the Rab.   
Presently there are only two known GDI proteins in humans that act on all known Rab 
proteins in the cytosol (Stenmark and Olkkonen, 2001).  In addition to these two known GDI 
proteins, there is another protein known as the Rab escort protein (REP) that has high levels of 
sequence similarity to the known GDI proteins.  The REP has the same function as the known 
GDI proteins, but only acts upon newly synthesized Rab proteins, allowing them to be 
prenylated by geranylgeranyl transferase at a C-terminal cysteine motif (CXXX, CC, CXC, 
CCXX or CCXXX where X is any other amino acid) via a covalent bond to the sulfur atom on 
the target cysteine (Itzen and Goody, 2011; Stenmark and Olkkonen, 2001).   
Once the GDI or REP has been removed, the Rab protein is then inserted into the 
specific target membranes.  The precise method of insertion is unknown, primarily due to the  
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Figure 1.5 - Rab5 conformations.  A) When Rab5 is GDP-bound it is in an inactive 
conformation.  Through the action of a GEF, the GDP is displaced in favour of a GTP 
molecule.  This then changes the Switch regions of Rab5 to an active conformation that can 
bind downstream effectors such as EEA1.  Rab5 contains intrinsic GTP hydrolysis activity, 
which is enhanced by the presence of a GAP protein.  B) Crystal structure of inactive state 
Rab5A-GDP complex. Switch I (purple), switch II (red) and the catalytic glutamine (Q79, 
orange) are highlighted.  The nucleotide structures, Mg
2+
 (grey spheres) and small water 
molecules are also shown.  C) Crystal structure of active state Rab5A-GTP complex. Drawn 
using PDB entries 1N6H (GTP) and 1TU4 (GDP) and coloured using Cn3Dv4.1 (Zhu et al., 
2003). 
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lack of identified GDFs.  It is known that the C-terminal hypervariable region of the Rab 
contains an essential conserved short sequence motif consisting of two hydrophobic aliphatic 
side chains (φ-x-φ motif, where φ is an aliphatic residue) that are involved in the hydrophobic 
interaction with the GDI and REP (Itzen and Goody, 2011).  It is possible that this same region 
is involved in the association of the GDF on the membranes of specific Rab targets (Pfeffer and 
Aivazian, 2004).   
Following Rab-GDP insertion into the membrane via the prenyl group, the Rab protein 
interacts with a GEF and becomes active following the exchange of GDP for GTP (Barr and 
Lambright, 2010; Seabra and Wasmeier, 2004; Stenmark and Olkkonen, 2001).  GEF proteins 
act by displacing the switch I region and allowing for the opening of the glycine brace region 
(Neuwald, 2009) .  They also aid in the displacement of bound Mg
2+
 molecules by displacing a 
threonine residue responsible for co-ordinating Mg
2+ 
(Nuoffer and Balch, 1994; Rossman et al., 
2005; Vetter and Wittinghofer, 2001).  This Mg
2+ 
is essential for stable binding of GNPs to the 
Rab protein, which also facilitates the removal of GDP.  Once GDP is removed, GTP can be 
recruited by the Rab protein (Barr and Lambright, 2010).  An example of a GEF protein is 
Rin1, a known GEF for Rab5 (Barbieri et al., 2004; Barbieri et al., 2003; Kong et al., 2007; 
Tall et al., 2001).  Once GTP-bound, the activated Rab protein can recruit effector proteins 
such as EEA1 to the endosome or vesicle, thereby promoting membrane fusion.  
Rab proteins are deactivated through their own intrinsic GTPase activity.  However, this 
activity is quite weak and is typically regulated through the addition of a GAP.  GAP proteins 
increase GTP hydrolysis by providing a catalytic ‗arginine finger‘ residue which helps catalyze 
the hydrolysis reaction.  It does this by effectively making the bound GTP a better substrate for 
nucleophilic attack by water, lowering the transition state energy for the hydrolysis reaction 
(Dumas et al., 1999; Scheffzek et al., 1997) (Fig. 1.6).  GAP proteins also stabilize the switch 
regions of Rab proteins, which further increase GTP hydrolysis (Scheffzek et al., 1998; 
Terzyan et al., 2004).  Following GTP hydrolysis, the Rab protein assumes its inactive 
conformation, and GDI is once again recruited, removing Rab5-GDP from the membrane. 
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Figure 1.6 – GTP hydrolysis in the Rab3A active site. In this proposed mechanism for 
Rab3A GTPase activity, several residues from the switch regions (I and II) of Rab3a (black and 
green) stabilize the γ phosphate (red) of GTP and a water molecule (blue).  During GTP 
hydrolysis, the phosphate group is subject to a nucleophilic attack by the water molecule, 
creating a pentavalent intermediate.  In the presence of an arginine finger provided by a GAP, 
the β and γ phosphates are stabilized, making the bound GTP a better substrate for nucleophilic 
attack (Dumas et al., 1999). 
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1.5.1 p85 is a Rab5GAP 
Rab5 is one of the best described human Rab proteins.  The active form of Rab5 is 
involved in the fusion of vesicles from the plasma membrane with the early/sorting endosome  
(Armstrong, 2000; Mills et al., 1999; Mohrmann and van der Sluijs, 1999; Somsel Rodman and 
Wandinger-Ness, 2000; Ullrich et al., 1994) (Fig. 1.10).  Active Rab5-GTP interacts with 
EEA1 which, in addition to binding Rab5, also binds to PI3P.  PI3P can be formed as either the 
lipid product of class III PI3K or via the dephosphorylation of the class 1A PI3K lipid product 
PI3,4,5P3 through the function of PI4- and 5-phosphatases (PI4- and 5-Pase) (Shin et al., 2005).  
EEA1:Rab5 forms a tether between the endocytic vesicle and the early/sorting endosome.  This 
tether allows for a soluble N-ethylmaleimide sensitive factor (NSF) attachment receptor 
(SNARE) complex to form, fusing the membranes together (Christoforidis et al., 1999; 
McBride et al., 1999; Mills et al., 1998; Rubino et al., 2000; Simonsen et al., 1998).  It is 
through SNARE-mediated fusion that many receptors are transported through the endosomal 
system. 
Recent evidence has shown that the p85 adaptor subunit of class IA PI3K acts as a 
Rab5GAP protein (Chamberlain et al., 2004).  This Rab5GAP activity was first discovered by 
analyzing the sequence similarity of p85 to known GAPs for the Rac/Rho/Cdc42 family of G-
proteins which are similar to Rab5 (Heasman and Ridley, 2008).  This analysis found that the 
BH domain of p85 contained putative GAP activity, and in vitro studies have confirmed it to 
have GAP activity towards both Rac1 and Cdc42 (Bokoch et al., 1996; Chamberlain et al., 
2004; Zheng et al., 1994).  A sequence alignment of a GAP protein for Cdc42 (Cdc42GAP) 
and p85 proteins revealed that p85 contains an arginine (R151) in its BH domain which 
corresponds to the arginine finger of the Cdc42GAP (Fidyk and Cerione, 2002).  However, it 
was revealed that p85 had a much lower GAP activity towards Cdc42 in comparison to the 
known Cdc42GAP protein.  Further analysis of the seqences of p85 and Cdc42GAP showed 
that the p85 BH domain lacked the residues used to stabilize the switch regions of Cdc42, 
requiring high concentrations of p85 to elicit significant GAP activity (Fidyk and Cerione, 
2002). 
When the RabGAP activity of p85 was measured towards Rab5 and Rab4, it was found 
that p85 also displayed GAP activity towards those proteins (Chamberlain et al., 2004; 
Chamberlain et al., 2010).   Rab5 and Rab4 are both involved in the trafficking of RTKs 
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through their degradation pathway (Hutagalung and Novick, 2011; Mitra et al., 2011; 
Stenmark, 2009).  Mutation of the R151 residue of p85, speculated by sequence similarity to be 
involved in GAP activity, showed only minor changes to the Rab5GAP activity of p85 
(Chamberlain et al., 2004; Chamberlain et al., 2010).  The mutation of another arginine residue 
in the BH domain (R274) showed that this residue was the arginine finger necessary for 
RabGAP activity (Chamberlain et al., 2004; Chamberlain et al., 2010). 
 Using this information, a model describing Rab5 regulation was proposed by our 
laboratory (Fig. 1.7).  Following RTK activation the PI3K complex (i.e., p85-p110) is recruited 
to the receptor through the interaction of the SH2 domains of p85.  The receptor is then 
internalized via either clathrin- or caveolin-mediated endocytosis.  Following the decoating of 
the vesicles, the GDI which masks the prenylation of Rab5 when in its inactive GDP-bound 
state is displaced, allowing Rab5 to embed itself in the membrane of the vesicle.  Rab5-GDP 
then interacts with the p85 subunit of PI3K, forming a complex upon the surface of the vesicle.  
At this point a Rab5GEF, most likely RTK-associated Rin1, displaces the Rab5-associated 
GDP with a GTP, thereby ‗activating‘ Rab5 allowing it to bind to EEA1 to form the tether 
required for membrane fusion.  Following the SNARE-mediated fusion event, the PI3K:Rab5 
complex dissociates from the RTK.  Aided by the Rab5GAP activity of p85, Rab5 hydrolyses 
the gamma-phosphate of its bound GTP, producing GDP.  Now in its inactive state, Rab5-GDP 
dissociates from the endosomal membrane, once again becoming GDI-bound. 
 
1.5.2 Tau Proteins Have Rab5GAP Activity 
 It has also been shown that the 383 amino acid Tau protein—a class of microtubule-
associated proteins (MAP)—known as Tau4 was observed to associate with Rab5 and appears 
to act as a Rab5GAP (personal correspondence, with Grégoire Morisse and Dr. Nicole Leclerc, 
Université de Montréal).  Microtubules are components of the cytoskeleton which play critical 
roles in a number of cellular processes including cell division, motility, intracellular trafficking, 
and maintaining cellular shape (Bhat and Setaluri, 2007; Lewis et al., 1988).  Microtubules are 
composed of α -tubulin heterodimers and are intrinsically dynamic polymers which form 
hollow, helical, cylindrical filaments containing thirteen tubulin dimers per turn (Desai and 
Mitchison, 1997; Li et al., 2002).  There are a number of proteins which associate with micro- 
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Figure 1.7 - Mechanism of Rab5 regulation.   Following RTK activation, PI3K (p85/p110) 
and Rin1 are recruited and the receptor complex is internalized by either clathrin- or caveolin-
mediated endocytosis.  GDI is displaced from Rab5, allowing Rab5 to embed itself in the 
membrane of the endocytic vesicle via its prenylation and to associate with the p85 subunit of 
PI3K.  Rin1, a RTK-associated Rab5GEF, displaces the GDP of inactive Rab5 and replaces it 
with a GTP, activating the Rab5 protein.  Rab5 then binds to EEA1, a PI3P-associating protein 
to form a tether between the endocytic vesicle and the early/sorting endosome which allows for 
SNARE proteins to fuse the vesicle to the endosome.  Following vesicle fusion, PI3K 
dissociates from the activated RTK.  Rab5 hydrolyzes its bound GTP with the help of the 
Rab5GAP p85, which causes it to be removed from the endosomal membrane and once again 
becomes GDI-bound. 
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tubules which bear the name MAP which are known to aid in assembly and disassembly in vivo 
(Goedert et al., 1991; Lewis et al., 1988). 
 Tau proteins are found primarily in the nervous system (Alonso et al., 2001; Goedert et 
al., 1989; Lewis et al., 1988).  In adult brain tissue six Tau proteins, all isoforms of the same 
Tau gene generated by alternative splicing, have been identified (Alonso et al., 2001; Goedert 
et al., 1989) (Fig.1.8).  Tau proteins are often differentiated into two primary domains, known 
as the projection domain and the assembly domain.  The projection domain is a 255-amino acid 
N-terminal segment which lacks the structures associated with microtubule binding.  This 
domain does not appear to be involved in pathological aggregation in diseases such as 
Alzheimer‘s disease and is known to bind to the membrane (Arikan et al., 2002).  The 
projection domain consists of zero to two of ‗insert‘ regions of 29 amino acids as well as 
several conserved domains common in all forms of Tau known as A1, A2, B, and C (Alonso et 
al., 2001; Friedhoff et al., 2000).  Conversely, the assembly domain is the C-terminal segment 
of the protein and contains three to four tubulin binding motifs consisting of 31 to 32 amino 
acids with a characteristic P-G-G-G motif (Alonso et al., 2001; Goedert et al., 1989).  It is this 
section of the protein which has been observed to aggregate in diseases such as Alzheimer‘s 
disease (Bertrand et al., 2010; Goedert et al., 1989).  There are also two conserved proline-rich 
regions located between the N-terminal projection domain and the C-terminal assembly 
domain.  Additionally, Tau proteins which are produced in peripheral neurons have been shown 
to also include an additional ―Big Tau‖ insert, though this form is not present in the central 
nervous system (Goedert et al., 1992). 
Tau proteins may contain as many as 85 phosphorylation sites, nine of which have been 
shown to be phosphorylated in human adult brain (Bertrand et al., 2010).  These sites appear to 
be involved in a number of disease states of tau, specifically in Alzheimer‘s disease where 
hyperphosphorylated tau proteins detach from microtubules and accumulate in neurons.  
Examples of this hyperphosphorylation can be found at disease-associated phosphorylation 
sites such as S262 or the sites forming the AT8 epitope seen in early-stage Alzheimer‘s disease  
(Augustinack et al., 2002; Bertrand et al., 2010; Kimura et al., 1996).  Tau proteins could also 
be involved in endocytic pathways, possibly in the retrograde transport of neurotrophins from 
the pre-synaptic terminal to the cell body (personal correspondence with Grégoire Morisse and 
Dr. Nicole Leclerc).   
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Fig 1.8 – Domain Structure of the Tau protein.  A) Tau protein is made of several different 
domains, each coded for by a different exon.  Exons 2 and 3 (I1 and I2) code for 29-residue 
domains, while exons 9, 10, 11, and 12 (R1, R2, R3, and R4) code for  homologous 31- to 32-
residue tubulin binding domains.  P1 and P2 are proline rich regions while A1, A2, B, and C 
are conserved domains.  In peripheral nerves there can also be a ―Big Tau‖ (exon 4A) insert 
added as well.  Included is a number of categorized possible phosphorylation sites. B) There 
are six primary isoforms of Tau which are obtained through alternate splicing. C) Alignment of 
tubulin binding domains. 
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1.6 Protein-Protein Interactions 
 All of the above pathways previously mentioned are dependent on protein-protein 
interactions, of which there are many different types present in any cellular system.  At their 
most basic, protein-protein interactions consist of intermolecular forces acting between the 
components of the protein complex whether it is transient or stable.  The most prominent of 
these interactions are ionic interactions as well as the hydrophobic effect (Gorham et al., 2011).  
The residues responsible for these interactions are often grouped in small secondary structures 
called binding domains.  Examples of these binding domains are the SH2 domain which binds 
to motifs consisting of a phosphorylated tyrosine plus several surrounding amino acids (Felder 
et al., 1993; Waksman et al., 1992).  These binding domains often have highly variable 
dissociation constants in the nanomolar to micromolar range. 
The affinity of two proteins for one another is a function of the free energy of 
association and their equilibrium binding constants.  The standard factors that are involved in 
these measurements in biochemistry are the equilibrium association and dissociation constants 
(KA and KD) (Roos et al., 1998; Zhou et al., 2008) as well as the free energy (ΔG) of the 
complex formation.  Under specific conditions, kinetic rate constants (k) are used to 
approximate the values of the equilibrium constants (K).  The association and dissociation 
constants relate to one another using the following formula: 
 
KA = 1/KD  
 
When it comes to reporting affinity constants, KD is often used to measure affinity because it is 
measured in molar units (Roos et al., 1998).  This is especially so when dealing with simple 
binding interactions with only two proteins.  KD specifically refers to the propensity of a binary 
complex to dissociate reversibly into its constituent components, and is described by the 
equation: 
 
KD = [B][L]/[BL] 
 
In this equation, B and L refer to the unbound ‗bait‘ protein and the ‗ligand‘ protein, 
respectively, while BL refers to the binary complex (Phizicky and Fields, 1995).    
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 Over the past 30 years a number of techniques have been developed to measure the 
binding affinity of two interacting biological molecules.  Genetic analysis and library-based 
techniques can be used to discover which proteins bind to one another, but actual quantification 
of the binding interactions generally requires physical binding analysis methods (Phizicky and 
Fields, 1995).  Binding affinities are analyzed by altering the concentration of one of the two 
proteins while keeping the other protein at a constant, but low, concentration.  From this, 
binding information can be gathered through different methods, from the change of 
fluorescence to change in optical density to simply measuring the concentration of the elutant 
(Phizicky and Fields, 1995).  It is also possible using kinetic analyses to approximate the KD of 
two proteins by measuring the on- and off-rate of the binding, thereby calculating the 
dissociation constant KD. 
 
1.7 Surface Plasmon Resonance 
 One of the techniques commonly used for measuring binding affinity between two 
molecules is surface plasmon resonance (SPR).  Surface plasmons are plasma waves which 
propagate across a metal-dielectric interface, typically a thin plane of gold or silver 
nanoparticles on a glass slide in the presence of a liquid under conditions of total internal 
reflection (Aslan et al., 2005; Jonsson et al., 1991; Rich and Myszka, 2000) (Fig.1.9A).  When 
a mass associates with the interface, it shifts the resonance energy of the surface plasmon in a 
detectable fashion.  This results in a change in the resonance angle, the angle light is reflected 
from the gold surface, which is detected and used to quantify the association between the 
interface and the analyte (Jonsson et al., 1991; Phizicky and Fields, 1995). 
 Gold is not a suitable surface for immobilizing proteins.  As such, many SPR sensor 
chips utilize a matrix of dextran, a flexible unbranched carbohydrate polymer.  Typically this 
dextran surface will contain some sort of reactive group or affinity resin which allows for the 
binding of a ‗bait‘ protein to the interface such as carboxymethyl groups (Fig.1.9B).  An 
example of this is the presence of a carboxymethylated dextran surface.  This surface will form 
N-hydroxysuccinimide esters from the carboxyl groups of the carboxymethylated dextran 
matrix via reaction with N-hydroxysuccinimide and N-ethyl-N'-(dimethylaminopropyl) 
carbodiimide hydrochloride in water.  These esters then react with proteins which are passed  
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Figure 1.9 – The CM5 Surface plasmon resonance chip. A) The CM5 chip is used with 
surface plasmon resonance.  Surface plasmons are generated by reflecting a beam of polarized 
light at a metal-dielectric interface.  While most of the light is reflected, some of the light 
propagates parallel to the interface under conditions of total internal reflection.  Bound to the 
gold monolayer of the metal-dielectric interface of a CM5 sensor chip are 100 nm dextran 
molecules which have been carboxylated in order to bind proteins via amine coupling. B) 
Structure of carboxymethylated dextran. C) The carboxyl-groups of the CM5 dextran surface 
are activated by a 1:1 solution of N-hydroxysuccinimide (NHS) and N-ethyl-N'-
(dimethylaminopropyl) carbodiimide hydrochloride (EDC) to give reactive succinimide esters.  
The desired ligand (i.e., Rab5) (in a buffer of appropriate pH to grant it a positive charge) is 
then passed over the surface and the esters react spontaneously with amino groups.  Any free 
amine group can react with this surface. 
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over the activated surface of the matrix, forming amides which covalently link the ‗bait‘ protein 
to the matrix (Johnsson et al., 1991) (Fig.1.9C).   
 As proteins all share a similar refractive index, there is a linear correlation between the 
shift in the resonance angle and the amount of protein bound at the surface (Jonsson et al., 
1991; Malmqvist, 1993).  This means that you can directly measure the binding of ligand 
proteins to the bait proteins in real time, allowing for the measurement of both the association 
and dissociation rates of the two molecules (Phizicky and Fields, 1995).  It has been noted that 
the data could be skewed by mass transfer effects caused by the movement of buffer containing 
solute over the sensor chip (Schuck and Minton, 1996; Shen et al., 1996), though these effects 
can be predicted by computer simulation found in many current model analysis software as 
well as experimentally (Schuck, 1996). 
 It is possible to calculate the total mass and even molar concentration of protein bound 
to a sensor chip.  SPR detectors measure signal in response units (RU) with 1000 RU 
corresponding to approximately 1 ng/mm
2
 of proteins on the SPR surface (Backmann et al., 
2005).  If the surface area is known, it is possible to calculate the mass of bound protein.  
Furthermore, if the relative masses and stoichiometry have been determined for the bait and 
ligand in the experiment, it is possible to determine the maximum binding (Rmax) of the ligand 
to the bait using the following equation from the BIAcore Sensor Surface Handbook: 
 
Rmax = Mass ligand x RU of immobilized Bait (RB) x Stoichiometry 
              Mass bait 
 
For example, Rab5 has a mass of approximately 24 kDa and p85 has a mass of approximately 
83 kDa.  Assuming 1:1 stoichiometry, 1000 RU of Rab5 should bind approximately 3460 RU 
of p85 at maximum saturation.  Through this method it should be possible to analyze the 
interactions between the various protein components observed in the model previously 
described (1.5.1).   
 
 
 
 
 
 24 
2.0 Hypothesis and Objectives 
Upon nucleotide exchange by a guanine nucleotide exchange factor (GEF) such as 
Rin1, Rab5 becomes GTP-bound (Barbieri et al., 2004; Barbieri et al., 2003; Kong et al., 2007; 
Tall et al., 2001).  Previous studies have shown that p85 functions as a Rab5GAP (Chamberlain 
et al., 2004).  Following binding of p85 to the PDGFR, p85 is known to undergo a 
conformational change in its SH2 domain regions which is known to derepress the catalytic 
activity of p110 (Miled et al., 2007; Piccione et al., 1993; Shoelson et al., 1993; Yu et al., 
1998).  Previous studies have not shown if this conformational change affects the Rab5GAP 
activity of p85.  It is possible that once p85 has dissociated from the PDGFR, it provides its 
catalytic arginine finger to the Rab5 protein, increasing its rate of GTP hydrolysis, deactivating 
Rab5. 
Previous studies by our lab have shown that p85 can associate with Rab5-NF 
(nucleotide-free), -GDP, and –GTP nucleotide binding states (Chamberlain et al., 2004).  While 
the binding of p85 to Rab5-GTP is expected as it is a Rab5GAP, its binding to Rab5-NF and 
Rab5-GDP indicates that p85 may have additional functions towards Rab5 beyond serving as a 
Rab5GAP.  The ability of p85 to bind Rab5-GDP suggests that p85 could fulfill the function of 
a Rab5GDF, removing the GDI protein from inactive, cytosolic Rab5-GDP, as it may recruit 
Rab5-GDP to membranes containing activated PDGFR:p85 complexes. 
 
2.1 Hypothesis 
 Activated PDGFR decreases the Rab5GAP activity of p85 in order to allow sufficient 
time for endosomal fusion events between the early/sorting endosome and the receptor-
containing endocytic vesicle.  In addition, p85 has different affinities towards Rab5 in its 
different nucleotide-associated states: Rab5-NF, Rab5-GDP, and Rab5-GTP. 
 
2.2 Objectives 
 The goals of this study were two-fold: 
 1) To test if the binding of PDGFR to p85 affects the observed Rab5GAP activity of 
p85.  To test this, peptides corresponding to the p85 binding site on the PDGFR in both its 
active (phosphorylated) and inactive (non-phosphorylated) states of PDGFR were purchased.  
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GAP assays (Anderson and Chamberlain, 2005) were performed to compare the GAP activity 
of p85 in the different states in the presence and absence of PDGFR peptide binding. 
 2) To test if the presence or absence of GTP and GDP affects the affinity of p85 for 
Rab5, both in the presence and absence of PDGFR peptide.  Surface plasmon resonance studies 
were performed to analyze the binding affinities of p85 to Rab5 in its three nucleotide bound 
states.  
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3.0 Materials and Methods 
 
3.1 Reagents and Supplies 
 All chemicals and reagents were of analytical grade or higher.  They were purchased 
from VWR or Sigma-Aldrich unless otherwise stated.  The glutathione Sepharose resin (GE 
Healthcare) were prepared according to the manufacturer‘s instructions and stored for up to 
several months at 4 C with no loss of stability.  The [ -
32
P]GTP (Cat # BLU506H) was 
purchased from PerkinElmer and likewise stored at 4 C.  All experiments using these isotopes 
met with all regulations mandated by the University of Saskatchewan.  The materials for use 
with the BIAcore-X surface plasmon resonance detector, including the CM5 sensor chips (Cat 
# BR-1000-12) and immobilization reagents (Cat # BR-1005-57), were purchased from GE 
Healthcare.  PDGFR peptide (sequence: DGGYMDMSKDESVDYVPML) and ppPDGFR 
peptide (sequence: DGGpYMDMSKDESVDpYVPML, with pY representing a phosphorylated 
tyrosine) were purchased from GeneScript of Piscataway, New Jersey, USA at >98% purity. 
 The following primary antibodies were used:  anti-p85 (B-9, Cat # sc-1637), anti-p110 
(I-19, Cat # sc-1637), anti-His6 (H-15, Cat # sc-803), anti-PDGFR (958, Cat # sc-432), anti-
pTyr (PY20) and all were purchased from Santa Cruz Biotechnology, Inc.  Secondary 
antibodies used were goat anti-rabbit (IRDye®800CW, Cat# LIC-926-32211), goat anti-mouse 
(IRDye®800CW, Cat# LIC-926-32210), goat anti-mouse (IRDye®680CW, Cat# LIC-926-
32220) and goat anti-rabbit (IRDye®680CW, Cat# LIC-926-32221), all purchased from LI-
COR Biotechnology. 
 
3.2 Methods 
 
3.2.1 Bacterial Strains and Growth Media 
 The pGEX6P1 (GE Healthcare) and pQE9 (Qiagen) vectors are designed for inducible 
protein expression in bacteria.  Transformation of bacteria with these vectors produces high 
levels of proteins fused to glutathione S-transferase (GST; pGEX) or His6 (pQE9) after 
induction with isopropyl -D-thiogalactopyranoside (IPTG).  Both vectors contain ampicillin 
resistance genes.  The pGEX6P1 vector contains a PreScission cleavage site (LEVLFQ*GP).  
The pGEX6P1 vector was used with all proteins produced except for the p110 clones generated 
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by Dielle Detillieux.  All plasmids were made previously by our laboratory.  All pGEX6P1 
plasmids containing inserts were expressed in Escherichia coli (E. coli) BL21 cells [F
-
 ompT 
hsdSB (r B
-
m B
-
) gal dcm] (Novagen) while all pQE9 plasmids containing inserts were expressed 
in E. coli M15pREP cells [Nal
S
, Str
S
, Rif
S
, Thi
-
, Lac
S
, Ara
+
, Gal
+
, Mtl
-
, F
-
, RecA
+
, Uvr
+
, Lon
+
] 
(Qiagen).  The production of the plasmid DNA was performed using E. coli TOP10 cells [F
- 
mcrA (mrr
-
hsdRMS
-
mcrBC) 80lacZM15 lacX74 recA1 ara139 (ara-leu)7697 galU galK rpsL 
(strR) endA1 nupG] (Invitrogen). 
 All cells were grown in Luria-Bertani Broth (LB, EMD Chemicals USA, Cat # 
1.10285.5007) containing 1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, and 1% 
(w/v) sodium chloride (NaCl) pH 7.0, per litre.  All plasmids contained an ampicillin resistance 
gene, therefore the E. coli BL21 and M15pREP cells were grown in LB containing 100 µg/mL 
ampicillin (LBA, Sigma-Aldrich).   
 
3.2.2 Eukaryotic Cell Lines and Growth Media 
 Mouse fibroblast cells, NIH 3T3, were obtained from American Type Culture 
Collection (CRL-1658) and grown in Dulbecco‘s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin G and 100 µg/mL 
streptomycin (P/S) (all purchased from Gibco) at 37 C in a 5% CO2 incubator. 
 Growth factor stimulations of NIH 3T3 cells were performed with PDGF-BB 
(Cedarlane, Cat# 220-BB-050) since these cells endogenously express the PDGFR.  PDGF-BB 
was resuspended in PDGF dilution buffer [10 mM acetic acid and 2 mg/mL bovine serum 
albumin (BSA)] and further diluted in spent starving media (DMEM + 1% P/S + 0.5% FBS) to 
a final concentration of 50 ng/mL.  PDGF stimulations were performed for 5 minutes at 37 C 
in a 5% CO2 incubator prior to cell lysis.   
To prepare lysates, 10 cm plates of cells (of approximately 85% confluence) were 
placed on ice and washed once with cold PBS.  Each 10 cm plate of cells was scraped into 1 
mL lysis buffer [50 mM N-(d-hydroxyethyl) piperazine-N‘-(2-ethanesulfonic acid), pH 7.5, 
150 mM NaCl, 10%(v/v) glycerol, 1%(v/v) Triton X-100, 1.5 mM MgCl2, 1 mM 
ethylenediaminetetraacetic acid, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, and 
also containing 10 µg/mL aprotinin, 10 µg/mL leupeptin, 1 mM 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF), and 1 mM sodium orthovanadate].  Cells 
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were incubated on ice for at least 10 minutes and centrifuged at 21,920 x g for 10 minutes in 
order to remove insoluble cellular debris.  Lysates were stored at -80 C. 
 
3.2.3 Purification of GST-Fusion Proteins 
 LBA volumes of 100 mL were inoculated with E. coli BL21 cells transformed with the 
appropriate plasmid encoding for the desired protein, which had been fused to GST.  Cells were 
allowed to grow overnight at 37 C with vigorous shaking.  The next day, four flasks each 
containing 1 L of LBA were inoculated with 25 mL of the overnight culture each.  The 
resultant culture was allowed to grow at 37 C until an OD600 of 0.6-0.8 was reached (~1.5 
hours).  IPTG was added to a concentration of 0.3 mM to induce protein expression.  After the 
addition of the IPTG the temperature was reduced to room temperature (~23 C) and the cells 
were allowed to grow overnight to promote slower protein induction and improve protein 
solubility.  Cells were harvested by centrifugation at 420 x g for 15 minutes at 4 C.  The cell 
pellet was then frozen at -20 C or lysed immediately. 
 For lysis, the cell pellet was resuspended in 10 mL of PreScission buffer (50 mM 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), pH 7.0, 150 mM NaCl, 1 mM 
EDTA, 1 mM DTT) containing 10 µg/mL aprotinin, 10 µg/mL leupeptin, and 1 mM AEBSF, 
all of which were added fresh.  The cells were lysed by the addition of 20 mg/mL lysozyme to a 
final concentration of 1 mg/mL and incubated on ice for one hour.  The lysates were sonicated 
six times for 10 seconds each on a setting of 2.5 using a Model 250/450 Sonifier (Branson 
Ultrasonics) with 60 seconds chilling on ice between bursts.  Triton X-100 was then added to a 
concentration of 1% in order to minimize protein-protein interactions and reduce impurities in 
the sample.  Samples were centrifuged at 12000 x g for 30 minutes at 4 C.  The supernatant 
was filtered through a 0.8 µm cellulose acetate membrane (Nalgene, Cat # 8-1020-05) and 
mixed with 2 mL of a 50% slurry of glutathione Sepharose resin (Amersham Biosciences, Cat# 
17-0756-01).   
The lysate and beads were incubated together for 45 to 60 minutes at 4 C while 
mixing.  The beads were recovered by centrifugation at 500 x g for 5 minutes and washed 5 
times with 50 mL of ice-cold PreScission buffer.  To cleave the protein of interest from the 
GST-tag, the bead-immobilized GST-fusion protein was resuspended in PreScission buffer and 
treated with 35 units of PreScission Protease (GST-3C, GE Healthcare Life Sciences, Cat# 27-
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0843-01) and allowed to cleave over a period of 48 hours at 4 C while mixing.  The bead 
solution was added to a gravity column and the desired protein was collected in the supernatant.  
The beads were washed with 16 mL of ice-cold PreScission Buffer, with the washes collected 
in aliquots equal to the bead volume (i.e. 1 mL).   
 
3.2.3.1 Ion Exchange Chromatography 
 p85 proteins were further purified using ion exchange chromatography.  As wild type 
p85 has a pI of 5.74 it was determined that a buffer with a pH above 7.5 would be ideal for 
anion exchange chromatography purification.  The proteins were buffer exchanged into Anion 
A buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl) using either an Amicon® Ultra-4 
Centrifugal filter unit (Millipore) or by dialysis.  They were then concentrated using the 
Centrifugal filter unit to a volume of 2 mL.  Protein concentration was determined by 
measuring the A280 and calculating protein concentration to ensure that the protein 
concentration was no higher than 25 mg/mL.  This was done using the Beer-Lambert Law in 
combination with the amino acid sequence and the known absorptions of Tyr and Trp at 280 
nm.   
 Using an ÄKTAFPLC™ (GE Healthcare) for the anion exchange, a Resource Q anion 
exchange column with a  bed volume of 1 mL (GE Healthcare) was washed with 20 column 
volumes of distilled water, followed by 20 column volumes of Anion A buffer to equilibrate the 
column.  The protein sample was injected into the fast protein liquid chromatography (FPLC) 
machine, allowed to bind to the anion resin, and washed with 20 column volumes of Anion A 
buffer.  The proteins were eluted from the column with a salt gradient using increasing 
concentrations of Anion B buffer (50 mM Tris-HCl, pH 8.0, 1 M NaCl) and collected in 0.5 or 
1 mL fractions.  Aliquots of these fractions were resolved using SDS-PAGE and visualized by 
Coomassie Blue stain to locate the purified p85.   
 
3.2.3.2 Dynamic Light Scattering 
 Aggregation and homogeneity of the purified protein solutions were analyzed using 
dynamic light scattering with a DynaPro-MS800 instrument (DynaPro, USA, Saskatchewan 
Structural Sciences Centre, U of S Campus).  Samples were diluted to concentrations between 
0.1 and 1 mg/mL and filtered to remove dust or other particulates.  Samples (40 to 100 μL) 
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were then placed in a DLS cuvette, removing as much air as possible.  The cuvette was placed 
into the Micro Sampler of the machine.  The proteins were analyzed with a beam of 
monochromatic light that is directed through the sample with the fluctuations of intensity of the 
light scattered by the particles of the solution analyzed.  With this data it is possible to 
characterize the size of the particles in question, and from that aggregation state and molecular 
mass. 
 
3.2.4 Purification of His6-Tagged Proteins 
 Growth and induction of bacterial cells were performed as per the same procedure as 
the GST-fusion proteins (3.2.3), with the addition of 10 μg/mL kanamycin when initially 
growing cells.  For lysis, the cells were resuspended in TALON Equilibrium/Wash Buffer (50 
mM sodium phosphate, pH 8.0, 300 mM NaCl, 20 mM imidazole) containing 10 µg/mL 
aprotinin, 10 µg/mL leupeptin, and 1 mM AEBSF, all of which were added fresh.  Cell lysis 
procedure was performed using the lysozyme procedure described for the GST-fusion proteins 
(Section 3.2.3) until lysates were ready to bind to beads. 
 The lysates were then incubated with 2 mL of a 50% slurry of TALON resin (Clontech, 
Cat# 635504).  The lysate and resin were incubated together for 45 to 60 minutes at 4 C while 
mixing.  The resin was washed by adding 40 mL of Equilibrium/Wash buffer, allowed to mix 
for 5-10 minutes, and centrifuging at 700 x g for 5 minutes.  This was performed five times.  
The resin was transferred to a gravity column and excess liquid was allowed to drain to just 
above the top of the resin.  The His6-tagged proteins were eluted from the resin using ten 1 mL 
aliquots of TALON Elution Buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 250 mM 
imidazole) and collected in fractions equal to the volume of the resin (i.e.,  1 mL). 
 
3.2.5 SDS-PAGE gels, Coomassie Blue Staining, and Western Blot Analysis 
 
3.2.5.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Proteins were resolved by SDS-PAGE for protein staining with Coomassie Blue or for 
Western blot analysis (Laemmli, 1970).  SDS-PAGE was performed using the Mini-Protean II 
apparatus (Bio-Rad).  Gels were cast between two glass plates with 1 mm spacers.  The 
resolving gels contained 7.5-15% acrylamide solution (29.2:0.8 acrylamide:bisacrylamide), 37 
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mM Tris-HCl, pH 8.8 and 0.1% (w/v) SDS.  Polymerization was initiated by the addition of 
0.06% (w/v) ammonium persulfate and 0.1%(v/v) N,N,N‘,N‘-Tetra-methylethylenediamine 
(TEMED).  After the resolving gel was polymerized, a 2 mL stacking gel containing 4.5% 
acrylamide solution, 125 mM Tris-HCl, pH 6.8, and 0.1% (w/v) SDS was poured on top of the 
resolving gel and a 10- or 15-well comb was inserted to form wells.  The stacking gel was 
polymerized with the same procedure as the resolving gel.  After the stacking gel was 
polymerized, the gel was assembled into the electrophoresis apparatus.  The protein samples 
were prepared in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 5%(v/v) -mercaptoethanol, 
2.3% (w/v) SDS, 0.1% (w/v) bromophenol blue, 10%(v/v) glycerol) and heated to 100 C for 5 
minutes.  The samples and molecular weight markers (Fermentas SM0671 or SM0661) were 
loaded on the gel.  Electrophoresis was performed at a constant voltage of 180 V in running 
buffer (25 mM Tris, 192 mM glycine, and 0.1% (w/v) SDS) until the bromophenol blue dye 
had run off the bottom of the gel as described by Laemmli (Laemmli, 1970). 
 
3.2.5.2 Coomassie Blue Stain Analysis 
To stain proteins, the gel was incubated in Coomassie Blue stain [0.14% (w/v) 
Coomassie Blue R-250 (Bio-Rad), 41.4%(v/v) methanol, and 5.4%(v/v) acetic acid] at room 
temperature for 20 minutes and destained in destaining solution [41.4%(v/v) methanol and 
5.4%(v/v) acetic acid]  until bands were visible.  The gel was imaged using the Gel-Doc 2000 
system using Quality One software (Bio-Rad). 
 
3.2.5.3 Western Blot Analysis 
 For Western blot analysis, the gels resolved by SDS-PAGE were soaked in transfer 
buffer (48 mM Tris-HCl, pH 9.2, 39 mM glycine, 0.038% (w/v) SDS, 20%(v/v) methanol) for 
15 to 20 minutes.  Meanwhile, 6 pieces of 3 MM filter paper (Whatman, Cat # 3030 700) were 
soaked into the transfer buffer and a nitrocellulose membrane (Whatman, Cat # 09301108) was 
hydrated in distilled water.  All 3 MM and nitrocellulose was cut to fit the gel (8.2 x 5.4 cm).  
The proteins were transferred using an Owl Panter
TM
 Semi-Dry Electroblotter (VWR, Cat # 
27372-374).  The apparatus was set up with three layers of soaked 3 MM paper on the base of 
the apparatus, followed by the SDS-PAGE gel, then the nitrocellulose membrane, and finally 
three more layers of the soaked 3 MM paper.  Air bubbles were removed by rolling a tube over 
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the layers.  The proteins were transferred to the nitrocellulose membrane at a constant current 
of 400 A for 15 minutes per gel. 
 The membrane was blocked in PBS Blocking Solution [10 mM sodium phosphate, pH 
7.3, 2.7 mM KCl, 137 mM NaCl supplemented with either 5% (w/v) Carnation skim milk 
powder (Canada Safeway) or 1% (w/v) BSA fraction V (EMD, Cat # 126593-25GM)] for 1 
hour at room temperature or overnight at 4 C.  Primary antibodies were diluted in the PBS 
blocking solution to 1 μg/mL for anti-PDGFR , anti-p85, anti-p110, and anti-His6; and 2 
μg/mL for anti-pTyr.  It should be noted that only the pTyr blots used a BSA-containing 
blocking solution with all others using milk blocking solution.  Each blot was incubated with 
primary antibodies for 1 hour at room temperature or overnight at 4 C.  The membrane was 
washed three times for 5 minutes in PBST (PBS + 0.05% (v/v) Tween-20).  Secondary 
antibodies, conjugated to IRDye®800 or IRDye®680 were diluted to a concentration of 
between 20 and 100 ng/mL into PBST with either milk or BSA fraction V as appropriate.   The 
membrane was incubated in the absence of light for 1-3 hours at room temperature and washed 
three times in PBST for 5 minutes each, again in the absence of light.  The membrane was 
scanned using the LI-COR Odyssey Infrared Imager (LI-COR) and analyzed with the Odyssey 
V3.0 software provided by the manufacturer. 
 
3.2.6 ppPDGFR Peptide Competition Assays to Disrupt PDGFR:GST-p85 Binding 
 Competition assays were performed to analyze the effectiveness of the ppPDGFR 
peptide and PDGFR peptide in binding competitively with wild type phosphorylated PDGFR to 
p85.  Wild type phosphorylated PDGFR was obtained by treating NIH 3T3 cells with PDGF for 
5 minutes prior to lysis.  To avoid non-specific interaction with the glutathione Sepharose 
beads, the lysates were pre-cleared by incubating them with the 100 μL of the beads for 30 
minutes.  The beads were then removed by centrifugation.  These cleared lysates were stored at 
-80 C until required.   
GST (serving as a negative control) and GST-p85 were isolated and separately 
immobilized on glutathione Sepharose beads.  Both were quantified using a Lowry protein 
assay (Sigma-Aldrich, Cat # TP0300).  Immobilized GST and GST-p85 proteins were diluted 
to a concentration of 0.1 µg/µL in PBS in a final volume of 100 µL.  To these samples were 
added either the ppPDGFR peptide or PDGFR peptide to concentrations of 1 µM, 10 µM, or 
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100 µM.  These samples were incubated at 4 C while mixing to allow interaction between the 
peptides and the GST-p85. 
 Pre-cleared PDGF-activated NIH 3T3 lysate (200 µL) was then added to the bead 
slurry.  The samples were again allowed to incubate at 4 C while mixing to allow interaction 
between the phosphorylated PDGFR from the cell lysate and the immobilized GST-p85 or GST 
control.  Protein complexes were collected by centrifugation at 500 x g for 1 minute and 
washed four times with 500 µL of HNTG
++++
 washing buffer [20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, pH 7.5, 10%(v/v) glycerol, 0.1%(v/v) Triton X-100, 150 mM 
NaCl, and also containing 10 µg/mL aprotinin, 10 µg/mL leupeptin, 1 mM AEBSF, and 1 mM 
sodium orthovanadate].  Samples were resuspended in 20 µL of SDS sample buffer, heated to 
100 C for 5 minutes and resolved by SDS-PAGE in duplicate.  One gel was transferred to a 
nitrocellulose membrane and analyzed by Western blot analysis for the presence of tyrosine-
phosphorylated PDGFR  (pTyr) and the other probed for total PDGFR . 
 
3.2.7 GTPase Activating Protein Assays (GAP Assay) 
 A modification of an existing procedure used in the lab (Anderson and Chamberlain, 
2005), the GAP assay is used to measure the hydrolysis of GTP by the Rab5 protein by 
measuring the amount of GDP produced.  The Rab5 protein was loaded with [ -
32
P]GTP which 
was hydrolyzed to [ -
32
P]GDP by the intrinsic GTPase activity of Rab5.  The [ -
32
P]GTP and 
[ -
32
P]GDP were separated by thin-layer chromatography (TLC).  The technique chosen for 
these analyses was a steady-state GAP assay where the amount of GDP generated via 
hydrolysis by Rab5 during a specific time in the presence of increasing concentrations of the 
p85 GAP protein was measured.   
 
3.2.7.1 Pre-Preparation for GAP Assays 
Prior to the assay, the TLC chamber was pre-equilibrated with the developing solvent 
(0.75 M KH2PO4; 180 mL) for 1-24 hours.  The PEI Cellulose F plates (VWR, Cat# EMD-
5579-7) were stored in a sealed, plastic bag to prevent hydration and stored at 4 C.  Plates 
were labelled using a pencil with 1.2 cm lanes denoted with 1.5 cm intervals between lanes 
starting 1.5 cm from each outside edge of the plate and 2 cm from the bottom of the plate. To 
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reduce wicking up the sides of the plate from the stand holding it, the sorbent material on either 
side of the plate was removed at 1 cm to create a barrier for the resolving liquid. 
 
3.2.7.2 Preparation of Reaction Mixture 
 A hydrolysis mixture consisted of the various concentrations of GAP protein (Tau or 
p85) in loading buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 1 mM DTT) containing 10 mM 
MgCl2 was prepared.  The total reaction volume was 15 µL, though the above hydrolysis 
mixture was made in a volume of 10 µL which would then be brought to the final volume with 
the addition of a master mix containing Rab5 diluted in loading buffer to a final concentration 
in 15 µL of 100 to 400 nM depending on the experiment, and 50 nM [ -
32
P]GTP (3000 
Ci/mmol).   In order to minimize GTP hydrolysis prior to the addition of the p85 to solution, 
the [ -
32
P]GTP was added to the Rab5 master mix solution and mixed by pipetting 
immediately prior to activation of the reaction.  Upon addition of the p85/Mg
2+
 (or Tau/Mg
2+
) 
samples were incubated at 24 C for 10 to 20 minutes, depending on the experiment, before 
being stopped by the addition of 3 µL of elution buffer [1% (w/v) SDS, 25 mM EDTA, 25 mM 
GDP, 25 mM GTP] and were heated for 2 minutes at 65 C. 
 
3.2.7.3 Separation and Analysis of Radiolabelled Nucleotides  
 Onto the thin layer chromatography (TLC) plate was applied 9 µL of the resulting 
stopped solution.  The sample was spotted in a 1.2 cm line over the course of 60 seconds and 
allowed to dry between applications.  A control sample containing only the nucleotide stock 
was spotted to assess the fraction of the pre-existing [ -
32
P]GDP already present in the 
radiolabelled nucleotide product, which varied considerably from batch to batch.  After the 
plate was loaded with all samples, it was allowed to dry for 15 minutes at room temperature. 
The plate was inserted into the TLC chamber where the developing solvent was several 
millimetres below the line marking the lanes so that the solvent did not smear the samples.  
Samples were allowed to migrate until the solvent front was 2 cm from the top of the plate 
(~1.5 hours).  After the plate was removed, it was dried at room temperature for 30 to 45 
minutes.  The plate containing the separated [ -
32
P]GTP and [ -
32
P]GDP was analyzed using a 
phosphorimager (Molecular Imager FX Pro Plus, Bio-Rad) and quantified using Quality One 
software (Bio-Rad).  The sum total of the signal of the GTP and GDP bands were taken (from 
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non-saturated images) and the percentage of total signal for each band was calculated.  The 
values from the nucleotide-alone wells were subtracted from this percentage since it was the 
background of [ -
32
P]GDP present in the absence of Rab5.   
 
3.2.8 Surface Plasmon Resonance (SPR) Analysis 
 Analysis of Rab5:p85 binding was performed using the BIAcore-X instrument (GE 
Healthcare) and analyzed using the BIAevaluation software (GE Healthcare, Structural 
Sciences Centre, U of S Campus).  This machine is a label-free system for detailed studies of 
biomolecular interactions that utilizes SPR.  SPR is an optical phenomenon arising in thin 
metal films under conditions of total internal reflection.  This can be used to measure the 
change in the concentration of molecules on the surface layer of solution in contact with the 
sensor surface. 
 
3.2.8.1 Preparation of CM5 sensor chip and binding of Rab5 
 Rab5 samples were buffer exchanged into a Rab5 loading solution (50 mM sodium 
acetate, pH 5.5, 50 mM NaCl) to a concentration of 0.1 mg/mL.  A CM5 sensor chip was pre-
equilibrated with BIAcore Running buffer (50 mM HEPES, pH 8.0, 150 mM NaCl).  The chip 
was then activated as per manufacturer‘s instructions with a 1:1 solution of N-ethyl-N'-
(dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) 
for 7 minutes at a flow rate of 5 µL/min across both flow cells (Fc1 and Fc2).  The Rab5 
solution was then bound to Fc2 only to a concentration of approximately 3000 response units 
(RU), or 3 ng/mm
2
  (Backmann et al., 2005) by directly binding to the carboxymethylated 
dextran surface of the CM5 sensor chip by amine coupling.  Fc1 did not receive any Rab5, and 
as such serves as a control for the experiments where the ligand protein will be flowed over 
both flowcells.  Both flowcells were washed three times with ethanolamine (provided with the 
EDC and NHS) for 7 minutes each at a flow rate of 5 µL/min to deactivate the surface.  Both 
flowcells were washed thoroughly with running buffer to remove any unbound protein, 
ethanolamine, or activating reagents.  In some experiments, Rab5 protein was bound with both 
Mg
2+
 and nucleotide (either GDP (Sigma-Aldrich, Cat # G7127)  or the non-hydrolysable GTP-
analogs GTP S (Sigma-Aldrich, Cat # G8634) or GppCp (Jena Biosciences, Cat # NU-405)).  
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In these cases MgCl2 and the appropriate nucleotide were added to the running buffer prior to 
the addition of p85.   
 
3.2.8.2 Preparation of p85 Ligand protein 
 p85 proteins were obtained via GST-fusion protein purification procedure (3.2.3) as 
well as all the other listed purification steps.  The p85 was buffer exchanged into p85 loading 
buffer which consisted of BIAcore running buffer with 0.05% Tween-20 added to keep the 
proteins from aggregating.  Concentrations of p85 used were chosen based on data gathered in 
the GAP assays and other binding experiments.  The concentrations chosen ranged from 0 µM 
to 30 µM, doubling each concentration (i.e., 1 µM, 2 µM, 4 µM, etc.) 
 
3.2.8.3 BIAcore Binding Assay 
 p85 ligand protein solutions were passed over both flowcells of the Rab5-immobilized 
CM5 sensor chips at a flow rate of 20 µL/min, with the flowcell without Rab5 serving as a 
control.  The order of different concentrations of p85 injected was determined randomly with 
each injection lasting for 120 seconds, followed by 120 seconds to measure dissociation prior 
to the resumption of constant flow of the BIAcore running buffer over the chip.  The signals for 
Fc1 (control) were subtracted from the signal from Fc2 (Rab5-bound) (Fc2-Fc1) in order to 
determine the relative change in RU (ΔRU). The peak values (around 100 to 110 seconds into 
injection) were then recorded and then converted into percent theoretical saturation of the chip.  
Maximum binding was plotted versus p85 concentration using the Prism software (GraphPad 
Software, Inc.).  Non-linear regression curve fitting allowed binding affinities to be determined. 
The flowcells were then washed after every run for 2 minutes with running buffer and after 
every second run with Regeneration buffer (50 mM glycine, pH 9.0, 500 mM NaCl 1% Tween-
20) to remove any accumulated p85, followed by another wash with running buffer.   
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4.0 Results 
 
4.1 Rab5 and p85 Protein Purification 
 Rab5 and p85 proteins were prepared in order to analyze the effect of PDGFR (through 
the use of the PDGFR peptide and ppPDGFR peptide) on p85:Rab5 interactions.  These 
interactions were analyzed using GAP assays to measure the effect of the peptides on the p85 
Rab5GAP activity, as well as for measuring the binding affinity of the two proteins to one 
another using SPR.   All experiments were performed using proteins that were purified by 
making GST-fusion proteins of the desired proteins using pGEX6P1 vectors expressed in 
protease deficient BL21 cells.  Protein expression was induced with IPTG and the bacteria were 
lysed to harvest the resultant GST-fusion proteins.  These proteins were isolated using 
glutathione Sepharose resin and GST-tags were removed by PreScission cleavage to yield 
purified proteins.  Samples were resolved by SDS-PAGE and visualized using Coomassie Blue 
stain and were also quantified using a Lowry protein assay (Fig.4.1). An additional clone of 
p85 containing both an N-terminal GST-tag and a C-terminal His6 was also assayed but was 
shown to have no GAP activity towards Rab5 (data not shown). 
 These proteins were then analyzed using a GAP assay to measure the Rab5GAP activity 
of p85 that had previously been shown by our lab (Chamberlain et al., 2004) (Fig. 4.2).  These 
early positive data prompted the continuation of further projects using these GAP assays (Fig. 
4.3).  Unfortunately the data gathered in subsequent GAP assays was not consistent to one 
another.  While nearly all of them showed p85 Rab5GAP activity, the exact activity varied 
greatly between protein batches.  Furthermore it was found that the p85 preparations displayed 
an ability to independently hydrolyze GTP in the absence of the known GTPase, Rab5 (Fig. 
4.4).  These preparations were also less effective at hydrolyzing GTP reaching 15-20% GTP 
hydrolysis at 32 µM p85 as compared to almost 60% GTP hydrolysis for the initial preparations 
(Fig. 4.3).  As p85 has not been shown to have any endogenous ability to hydrolyze GTP 
previously, it was believed that the purity of the proteins was the issue.  As such, additional 
purification steps were considered. 
 Additionally, subsequent GAP assays displayed lower GTP hydrolysis than earlier 
studies which seemed to go beyond simple batch-to-batch variation.  Spectrophotometric 
analysis of purified Rab5 samples suggested that this may have been caused by the presence 
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Figure 4.1 – Purification of Rab5 and p85 proteins.  Rab5 and p85 proteins were generated 
as GST-fusion proteins in BL21 cells.  The BL21 cells were lysed and the proteins were 
recovered using glutathione Sepharose resin.  The beads were washed and the GST-tag was 
removed using PreScission protease. The cleaved proteins were recovered and concentrated to 
a final concentration of 3-5 µM for Rab5 and 70-80 µM for p85 using a concentrator and 
quantified using a Lowry assay.  The indicated amounts were then resolved on either a 10% 
(p85) or 15% (Rab5) SDS-PAGE gel and visualized with Coomassie Blue stain for Rab5 (A, 
left) and p85 (B, left).  A duplicate gel was also prepared and the proteins were transferred to a 
nitrocellulose membrane and blocked in milk.  Following blocking, the membranes were 
incubated with a primary antibody against Rab5 (A, right) or p85 (B, right), then with a 
secondary antibody containing a fluorescent tag.  The results of the Western Blot were 
visualized using the LI-COR Odyssey Infrared Imager. 
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Figure 4.2 – Experimental Model of GAP assay.  Rab5 samples were loaded with [α32P]GTP 
and incubated +/- p85 +/- ppPDGFR peptide or PDGFR peptide as per the directions above and 
allowed to react for 10-20  minutes.  Reactions were then stopped with 3 µL of a buffer 
containing 1% SDS, 25 mM EDTA, and 25 mM each of unlabelled GDP and GTP.  These were 
heated to 65 C for 5 minutes to elute the nucleotides from Rab5, spotted onto a PEI Cellulose 
F-Plate, and resolved using a buffer containing 0.75 M KH2PO4, pH 4.0.  Plates were allowed to 
dry and data was captured using a Storage Phosphor Screen and a phosphorimager. 
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Figure 4.3 – Analysis of p85 Rab5GAP activity using GAP assay. Increasing concentrations 
of p85 were incubated with or without 400 nM Rab5 in the presence of Mg
2+
 and [ -
32
P]GTP 
for 15 minutes in order to measure the GTP hydrolysis of the purified p85 sample compared to 
the GTP hydrolysis in the p85+Rab5 samples. A) Nucleotides were resolved using PEI 
cellulose-F TLC plates with a 0.75 mM KH2PO4 developing solvent.  The plates were then 
exposed to a storage phosphor screen and imaged using a Phosphorimager. The results shown 
are typical for three independent experiments. B) Pixel densities were quantified using the Gel-
Doc 2000 system using Quality One software and plotted using Microsoft Excel.  Mean +/- 
standard deviation for three independent experiments.  
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Figure 4.4 – p85 samples appear contaminated with an unknown GTPase protein. 400 nM 
Rab5 was incubated in the presence of Mg
2+
, [ -
32
P]GTP, and increasing concentrations of p85 
for 15 minutes.  Similar control assays were also carried out in the absence of Rab5. A) 
Nucleotides were resolved on PEI Cellulose F TLC plates as per standard GAP assay 
procedure.  B) Pixel densities were quantified using the Gel-Doc 2000 system using Quality 
One software and plotted using Microsoft Excel.  Mean +/- standard deviation for three 
independent experiments. 
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of a Rab5-GDP that was likely not efficiently exchanged for [ -
32
P]GTP by EDTA and Mg
2+
 
treatments.  Typically, ultraviolet spectra of protein samples had a ‗shoulder‘ at 260 nm caused 
by the presence of phenylalanine residues (with some contribution from tyrosine and 
tryptophan), but this should be proportional to the much larger signal absorbed at 280 nm from 
phenylalanine, tyrosine, tryptophan, and—to a much lesser extent—cysteine residues (Pace et 
al., 1995) (Fig. 4.5).  The result is an A280/A260 ratio that may be calculated from the amino acid 
composition.  The most common contaminant in protein samples which absorbs at 260 nm are 
nucleotides and nucleic acids (Glasel, 1995).  As Rab5 is known to be a small monomeric G-
protein that binds nucleotides (specifically GDP and GTP) in vivo, and that it shows intrinsic 
GTP hydrolysis activity, it was likely  that GDP was remaining bound to Rab5 following its 
purification. 
 In order to analyze what fraction of the A260 signal was provided by the protein and how 
much was provided by the nucleotide the concentration of Rab5 (#Tryp = 2, #Tyr = 5, #Cys = 
4, #Phe = 10) was determined.   Using the formula of (#Trp x 5,500) + (#Tyr x 1,490) + (#Cys 
x 125) the 280 of Rab5 is 18950 M
-1
cm
-1 
(Pace et al., 1995).  Using data provided by Dr. 
Stanley Moore, based on the works of multiple studies (Edelhoch, 1967; Pace et al., 1995; 
Wetlaufer et al., 1958), the 260 of Rab5 was calculated using the formula 260 (M
-1
cm
-1
) = 
(#Phe x 144) + (#Tyr x 600) + (#Trp x 3,300).  From this, an 260 of Rab5 was determined to be 
11,040 M
-1
cm
-1
.  The 260 of guanosine has been reported as 11,500 M
-1
cm
-1
(Cantor et al., 
1970).  An A260 measurement was used to calculate Rab5 protein concentration using the Beer-
Lambert Law (A= cl where A = absorbance, c = concentration, l = path length).  The 
theoretical absorbance of Rab5 at 260 nm based on the concentration determined at 280 nm 
was then calculated, and subtracted from the observed A260 (Fig. 4.5B).  The difference was 
presumed to be due to a nucleoside and, using the 260 of guanosine (same 260  for guanine) the 
relative percent saturation was calculated.  It was determined that the purified Rab5 samples 
were contaminated with nucleotide, with saturations ranging from 45% to 100%. 
 
4.2 Optimization of Protein Purification 
 Both the p85 and Rab5 samples required additional purification steps to remove 
contaminants.  For the p85 samples, GTP-hydrolyzing activity contaminants needed to be 
removed (4.2.1).  Rab5 required purification in order to minimize bound nucleoside (4.2.2). 
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Figure 4.5 – Rab5 contains bound nucleosides.  A) Purified Rab5 and p85 were subjected to 
spectrophotometric analysis measuring the absorptions between 230 and 320 nm in increments 
of 5 nm.  Absorptions were entered into Microsoft Excel and graphed.  The absorbance 
spectrum of purified p85 is typical for proteins not contaminated with nucleotide, with a 
distinct trough at 255 nm.  Rab5 shows a markedly higher signal than is typical at 260 nm, 
which is indicative of nucleic acid contamination. B) Sample calculation used to determine % 
nucleotide saturation of Rab5. 
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4.2.1 Alteration of GST-p85 Protein Purification Procedure 
The first series of trials involved the addition or substitution of reagents to the standard 
PreScission protease buffer that was used during the purification of the GST-p85 proteins.  The 
standard lysis buffer used contains 1% Triton X-100, a non-ionic surfactant capable of breaking 
down the plasma and nuclear membrane of a cell.  This detergent was substituted for the less 
stringent detergent NP-40 at a concentration of 0.5%.  In some trials, the concentration of NaCl 
was raised to 0.5 M instead of the standard 0.15 M in order to disrupt ionic bonds which may 
be forming between p85 and other proteins.  In order to try to break any non-covalent bonds 
present between p85 and an unknown protein, 0.5 M urea was also added to on treatment.  
BL21 cells that were induced to produce GST-p85 were lysed in all of these different buffers.  
Soluble GST-p85 proteins were recovered using glutathione Sepharose resin and cleaved from 
the GST tag using PreScission protease.  The resultant proteins were analyzed using a GAP 
assay with and without Rab5 proteins. 
 The percent GTP hydrolyzed was very similar across all of the different conditions (Fig. 
4.6A).  The only exception to this appeared to be the condition where the standard PreScission 
buffer used during p85 purification contained 0.5 M NaCl which resulted in increased GTP 
hydrolysis in the absence of Rab5.  Due to the fact that all of the other conditions yielded very 
similar results, it was decided that this experiment was an outlier and represented human error.  
All of the p85 samples were pooled together except for the one isolated in the standard 
PreScission buffer with 0.5 M NaCl.  This pooled p85 sample was further analyzed for GTP 
hydrolysis and Rab5GAP activities over a concentration range of p85 (Fig. 4.6B).  It was found 
that the purified p85 continued to show the ability to hydrolyze GTP (~5%) independent of 
Rab5 in all of the conditions regardless of these changes to the PreScission buffer during 
purification.  As such, it was decided to utilize the original purification procedure, but more 
thoroughly wash the GST-p85 proteins while bound to glutathione Sepharose resin prior to the 
addition of PreScission protease to remove any contaminants which may have bound to p85 or 
the resin itself. 
 
4.2.2 Removal of Contaminating Nucleotide from Rab5 
 In order to efficiently load new nucleotide (i.e., [α-32P] GTP, GTP, GTPγS, and GppCp) 
onto Rab5, bound nucleotides associated with Rab5 during purification must first be removed.   
 45 
 
Figure 4.6 – Comparison of Rab5-dependent and Rab5-independent GTP hydrolysis in 
the presence of p85 purified using different purification conditions.  A) p85 proteins were 
purified using standard PreScission buffer (50 mM Tris-HCl, pH 7.0, 150 mM NaCl, 1 mM 
EDTA, 1 mM DTT) under six different modifications.  These include increasing the 
concentration of NaCl to 0.5 M and adding 0.5 M urea. In the standard protein purification 
procedure 1% Triton X-100 is added to cell lysates prior to centrifugation, though three of six 
samples substitute this for 0.5% NP-40.  Following purification, p85 samples were assayed at a 
single concentration (15 µM) for GTP hydrolysis in the presence or absence of 400 nM Rab5.  
B) GTP hydrolysis of a titration of p85 pooled in all above conditions except normal 
PreScission + Triton X-100+ 0.5 M NaCl in the presence and absence of Rab5.  Experiment 
was done twice with the mean +/- standard deviation shown.  
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As Rab5 requires Mg
2+
 to bind nucleotide effectively (Pan et al., 1996), EDTA was added to 
ten times the 1 mM EDTA normally found in PreScission buffer during Rab5 purification.  It 
was hoped that the higher concentration of EDTA would chelate the Mg
2+
, thereby removing it 
and any bound nucleotide from Rab5.  However, spectrophotometric analysis of the purified 
Rab5 samples continued to suggest the presence of nucleotide at roughly the same 
concentrations as in Rab5 proteins purified in PreScission buffer containing normal 
concentrations of EDTA. 
 Two published methods (John et al., 1990; Simon et al., 1996) were modified to be 
used with what materials were available in our laboratory in an effort to produce nucleotide-
free Rab5.  GST-Rab5 was immobilized on glutathione Sepharose resin and treated with the 
high-EDTA PreScission buffer to remove any free Mg
2+
 from the solution.  The beads and their 
bound GST-Rab5 proteins were treated with alkaline phosphatase and/or snake venom 
phosphodiesterase overnight.  The alkaline phosphatase hydrolyzes phosphate bonds, while 
phosphodiesterase removes diester bonds.  These two enzymes should degrade any GDP or 
GTP that was Rab5-associated into guanosine monophosphate (GMP).  The hydrolyzed GMP 
would be expected to have a lower affinity for Rab5 and be released.  The original procedure 
called for the addition of GppCp, a non-hydrolyzable form of GTP, to be added during the 
alkaline phosphatase treatment, presumably to replace degraded GDP which was the original 
reason for the phosphodiesterase.  This step was omitted as it was not seen to be necessary. 
However, spectrophotometic analysis showed similar spectra to the Rab5 not treated with these 
enzymes (data not shown, refer to Fig. 4.5).  Furthermore, Rab5 proteins treated with snake 
venom phosphodiesterase showed marked degradation compared to those not treated, as seen in 
the bead washes following PreScission cleavage (Fig. 4.7). 
 
4.2.3 Ion Exchange Chromatography of p85 
 It was observed that in many cases purified p85 samples contained multiple small 
molecular weight bands aside from the expected 84 kDa band representing p85 on a Coomassie 
stain gel.  The most prominent of these was a band of approximately 75 kDa (Fig. 4.8A). In an 
effort to further purify p85, PreScission-cleaved p85 samples were subjected to ion exchange 
chromatography.  Because p85 has a pI of 5.74 it was determined that anion exchange  
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Figure 4.7 – Removal of GTP/GDP from Rab5 leads to degradation of Rab5.  GST-Rab5 
proteins were immobilized on glutathione Sepharose resin and separated into three batches.  
The first batch was cleaved with PreScission protease.  After 48 hours the beads are washed 
with cold buffer and the fractions are collected.  The second batch was treated with 5 units/mL 
alkaline phosphatase overnight at 18 C, washed to remove enzyme, and treated with 
PreScission protease and collected. The third batch was treated with alkaline phosphatase as 
above, washed, and treated with 5 units/mL snake venom phosphodiesterase overnight at 15 C, 
washed, and treated with PreScission protease and collected.  Aliquots from all samples were 
resolved using 15% SDS-PAGE and visualized with Coomassie Blue stain.  
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Figure 4.8 – Ion exchange chromatography improves p85 purity.  p85 proteins were 
purified using the standard protein purification procedure and resolved using 12% SDS-PAGE 
and visualized with Coomassie Blue stain.  A) Purified p85 bovine (bov) and human (hu) were 
resolved using a 10% SDS-PAGE gel. B) p85 proteins washed from glutathione Sepharose 
resin after cleavage from their GST-tags by PreScission protease.  Shown are aliquots (10 µL) 
of the first six washes of the beads which were collected in 2 mL volumes.  C) Elution profile 
of p85 purification using ÄKTAFPLC™.  Blue line represents the A280 reading, denoting protein 
in a particular fraction.  Light green denotes the progress of the programmed procedure, brown 
denotes the salt gradient from 0.05 M to 1 M NaCl.  D) Pooled p85 after being purified using 
anion exchange chromatography.  Included is an undiluted sample as well as a 1:5 dilution and 
a 1:25 dilution, each with 10 µL loaded onto the gel, resolved and stained with Coomassie 
Blue. 
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chromatography at pH 8.0 using a Resource Q column would be the most effective means of 
purifying p85.  This technique resulted in a significant improvement in the purity of p85 (Fig. 
4.8B and C).   However, these purified p85 samples did not appear to provide different GAP 
assay results compared to the p85 proteins which were not purified with anion exchange 
chromatography (data not shown). 
 
4.2.4 Ion Exchange Chromatography of Rab5 
 It was decided to also attempt to further purify Rab5 by ion exchange chromatography 
to attain the most pure proteins possible for future assays.  In addition, it was hoped that the 
technique‘s ability to separate proteins based on charge would allow for the separation of 
contaminating nucleotides, or even the separation of Rab5 in different nucleotide-bound states.  
As Rab5 has a pI of 8.22, it was decided that cation exchange chromatography in the range of 
5.5 to 6.5 using a Resource S column would be optimal.  Unfortunately, all attempts to have 
Rab5 bind to the cation exchange media failed, as did attempts to bind Rab5 to anion exchange 
media under the same conditions used to purify p85. 
 
4.2.5 Dynamic Light Scattering (DLS) Analysis of p85 and Rab5 Samples 
 DLS analysis was carried out on all proteins intended for SPR studies.  DLS allows for 
the measurement of the diameter of particles in solution, and can be used to analyze if there are 
higher or lower molecular weight particles in solution aside from the target protein.  Using this 
technique it is possible to identify the presence, and even the percent total mass, of particles 
which do not match the desired size of the protein, providing a measure of 
heterogeneity/homogeneity of the samples.  Using standard data on the relative hydrodynamic 
radius of globular proteins of specific molecular weights, it is possible with a fair degree of 
certainty to estimate the molecular mass of the detected particles.  When originally used to 
analyze p85 in its original BIAcore buffer (50 mM HEPES, pH 8.0, 150 mM NaCl), a large 
number of particles of high hydrodynamic radius were detected which was suggestive of 
aggregation (Fig. 4.9A).  In an effort to reduce or prevent this aggregation, 0.05% Tween-20 
was added to the above buffer.  This greatly decreased the amount of high hydrodynamic radius 
particles and produced a solution which was monomodal with a polydispersity between 6-12%.  
Polydispersity measures the fraction of particles in the sample which are of non-uniform size.   
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Figure 4.9 – Dynamic light scattering spectra of p85.  p85 proteins were analyzed by DLS to 
analyze the hydrodynamic radius (Rh) of the particles in solution and what percentage of the 
total solute concentration was made up of particles of that radius (%Intsty = Percent Intensity).  
Each individual Bar represents the intensity of a given Rh, while each colour defines a different 
population highlighted by the analysis software. A) 1.0 mg/mL p85 in standard BIAcore 
Running buffer with no Tween-20. B) 0.1 mg/mL p85 in BIAcore Running buffer (50 mM 
HEPES, pH 8.0, 150 mM NaCl) in the presence of 0.05% Tween-20 to prevent aggregation.  
C) 1.0 mg/mL p85 BIAcore Running buffer (50 mM HEPES, pH 8.0, 150 mM NaCl) in the 
presence of 0.05% Tween-20 to prevent aggregation.  D) 1.0 mg/mL p85 in 50 mM sodium 
acetate, pH 7.0, 50 mM NaCl.   
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These results indicate that between 88% and 94% of the solution contained particles of the 
same hydrodynamic radius as p85 as a monomer or dimer at concentrations of 0.1 and 1.0 
mg/mL (Fig. 4.9B and C).  As detergent may interfere with GAP activity, only p85 samples 
used in SPR studies contained the added 0.05% Tween-20.  It was also observed that if p85 is 
stored in a solution of 50 mM sodium acetate, 50 mM NaCl, pH 7.0, it also appeared to have 
equally low polydispersities (Fig. 4.9D).  However, it was observed in binding studies that 
storage in this buffer appears to ablate the ability of p85 to bind to Rab5 effectively and as such 
this buffer was not used for SPR studies. 
Rab5 samples were observed to have similar polydispersities as the p85 samples in the 
presence of Tween-20 in the absence of any added detergents, and it was determined they were 
not needed to ensure monomodal distribution (data not shown).   
 
4.3 ppPDGFR Peptide Competes with Activated Wild Type PDGFR 
 The p85 protein is known to bind to phosphorylated PDGFR through both of its SH2 
domains which causes a conformational change in p85 (Piccione et al., 1993; Shoelson et al., 
1993).  In order to ascertain if this conformational change impacts the GAP activity previously 
shown for p85 towards Rab5 in vitro, GAP assays would have to be performed in the presence 
of activated PDGFR.  However, due to the difficulties associated with using large eukaryotic 
integral membrane receptor protein complexes in such an assay, a small phosphopeptide called 
ppPDGFR peptide (sequence: DGGpYMDMSKDESVDpYVPML) was used.  In addition to 
the ppPDGFR peptide the corresponding nonphosphorylated peptide, called PDGFR peptide 
(sequence: DGGYMDMSKDESVDYVPML), was also used as a negative control.  Previous 
studies using the same peptides showed that only the phosphorylated peptides bound to p85 and 
induced the appropriate conformational change (Panayotou et al., 1992; Shoelson et al., 1993). 
 Experiments were performed to assess the functionality of these custom synthesized 
peptides prior to using them in the GAP assays.  A GST-p85 pull-down assay had been used 
previously to bind activated and phosphorylated PDGFR from mammalian cell lysates.  Each 
peptide was tested for its ability to compete with full-length PDGFR binding to GST-p85 
immobilized on glutathione Sepharose resin (Fig. 4.10A).  NIH 3T3 cells were activated for 
five minutes with PDGF and lysed in the presence of sodium orthovanadate and protease 
inhibitors to preserve the phosphorylated state and integrity of the activated PDGFR. 
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Figure 4.10 – ppPDGFR peptide competes with activated PDGFR for p85 binding while 
the corresponding unphosphorylated peptide does not.  A) Experimental strategy.  GST-p85 
fusion proteins were immobilized on glutathione Sepharose resin and incubated in the presence 
or absence of either ppPDGFR peptide or PDGFR peptide.  Lysates from NIH 3T3 cells which 
had been activated for 5 minutes with PDGF were added and activated PDGFR were allowed to 
bind.  Non-bound proteins and/or peptides were washed off.  B) The beads were recovered and 
resolved on a 7.5% SDS-PAGE gel and transferred to a nitrocellulose membrane.  The 
membrane was analyzed by Western blot analysis. The membranes were blocked in either milk 
(PDGFR) or BSA fraction V (pTyr).  The results of the Western Blot were visualized using the 
LI-COR Odyssey Infrared Imager.  The results shown are typical for at least three independent 
experiments. 
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 GST-p85 was diluted to a concentration of 0.1 µg/µL bound to glutathione Sepharose in 
a total volume of 100 µL.  The samples were pre-incubated with increasing concentrations of 
either the ppPDGFR peptide or the PDGFR peptide.  PDGF-activated NIH 3T3 cell lysate (200 
µL; 20% of a 10 cm plate) was added and allowed to bind with immobilized GST-p85.  The  
beads were washed thoroughly and analyzed by Western blotting to detect both PDGFR and 
tyrosine phosphorylated PDGFR proteins (pTyr) (Fig. 4.10B).  In the absence of peptide, 
tyrosine phosphorylated PDGFR bound to the immobilized GST-p85 as expected but not to the 
control protein, GST.  The ppPDGFR peptide competed with the wild type activated PDGFR at 
concentrations as low as 1 µM and showed complete competition at 10 µM.  In contrast, the 
unphosphorylated PDGFR peptides did not compete with the activated PDGFR from the NIH 
3T3 lysate.  This shows that the ppPDGFR peptide is a suitable alternative to wild type 
activated PDGFR when studying the effects of the PDGFR on p85:Rab5 interactions. 
 
4.4 GTPase Activating Protein (GAP) Assays 
 In order to determine the effectiveness of a protein to serve as a GAP (i.e. p85) for other 
proteins (i.e.,  Rab5) the GAP assay was used.  This assay consists of loading the Rab5 GTPase 
protein with the [α-32P]GTP and incubating it with increasing concentrations of the p85 
Rab5GAP protein for a set amount of time prior to stopping the reaction.  The samples are then 
loaded onto a PEI cellulose-F plate and resolved.  The PEI (polyethylenimine) acts as a cationic 
polymer that will separate purine and pyrimidine nucleotides based on their respective 
nucleosides and free bases (Gupta et al., 1976; Reyes, 1972).  The [α-32P]GTP and [α-32P]GDP 
were resolved using a buffer of 0.75 M KH2PO4 as established previously (Anderson and 
Chamberlain, 2005).  Data from the TLC plates were captured using a storage phosphor screen 
and quantified using a phosphorimager (Fig. 4.2). 
 A series of GAP assays were performed with different combinations of proteins, though 
the primary focus was on the analysis of p85 GAP activity towards Rab5.  In addition, due to 
observations made during the course of this study, the GAP activity of p85 towards other Rab 
proteins (Rab4, Rab7, and Rab11) were also studied.  Lastly, the Rab5GAP activity of the Tau 
protein was studied in collaboration with Grégoire Morisse of the laboratory of Dr. Nicole 
Leclerc at the Université de Montréal in Montreal, Quebec, Canada. 
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4.4.1 GAP Assay Analysis of p85:Rab5 Interactions 
 Previous work in our lab had shown that p85 interacts with Rab5, functioning as a 
Rab5GAP (Chamberlain et al., 2004).  A titration of p85 was chosen for analysis ranging from 
0 µM p85 to 32 µM p85, diluted serially.   These p85 samples were incubated with 200 to 600 
nM of Rab5 loaded with [α-32P]GTP and assayed for 10 to 20 minutes depending on the 
experiment and the observed of activity of the protein preparations in question.  Previous data 
had shown that there was 570- to 1700-fold increase in the rate of Rab5-mediated GTP 
hydrolysis upon addition of high concentrations of p85.  This was calculated by taking the 
average percentage of GTP hydrolyzed by Rab5 in the presence of p85 at higher concentrations 
and dividing it by the average percent GTP hydrolyzed of Rab5 in the absence of p85 (Fig. 
4.3).  In order to reduce batch variation between radiolabelled GTP, a nucleotide-alone sample 
was also run with the % GDP subtracted as a background control.  This value depended on the 
batch of the p85 and Rab5 preparations used, and was consistent with previously recorded data 
that supported p85 being a Rab5GAP (Chamberlain et al., 2004).  However, further assays of 
this type showed a marked drop in the degree of GTP hydrolysis, likely tied to issues 
surrounding protein purity (Fig. 4.4). 
 
4.4.2 Impact of PDGFR Binding on p85 GAP Activity Towards Rab5 
 Further GAP assays were performed using the synthesized PDGFR-analog peptides to 
analyze the effects of the PDGFR protein binding on Rab5GAP activity of p85.  These assays 
were performed using the same procedure as the standard p85:Rab5 GAP assays, but with the 
addition of 100 µM of the peptides to the p85 reaction mixture. These peptides were allowed to 
bind to p85 for 30 minutes at 4 C prior to initiation of the reaction.  GTP hydrolysis (%) 
results from each of the three conditions (p85:Rab5, ppPDGFR:p85:Rab5, and 
PDGFR:p85:Rab5) were normalized to that for Rab5 alone and plotted on a graph (Fig. 4.11).  
It was determined that the PDGFR peptide and ppPDGFR peptide did not affect the ability of 
p85 to function as a Rab5GAP. 
 
4.4.3 Testing the Tau Protein as a Possible Rab5GAP 
 Tau proteins are proteins which are found primarily in neurons of the central nervous 
system  (Drubin and Kirschner, 1986).   Their  primary  function  is  to  stabilize  microtubules,  
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Figure 4.11 – Comparison of GAP activity of p85 towards Rab5 in the presence and 
absence of ppPDGFR peptide and PDGFR peptide. Purified p85 proteins (15 μM) were 
incubated with 100 µM of peptide (ppPDGFR peptide or PDGFR peptide) for 30 minutes at 4 
C prior to performing the standard GAP assay. The % GTP hydrolysis was then measured, and 
normalized to the % GTP hydrolysis of Rab5 in the absence of p85 and/or peptide (2%).  The 
results shown are the average of three separate experiments +/- standard deviation. 
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though Tau has also been shown to be involved in other processes such as signal transduction, 
actin cytoskeletal regulation, and vesicle transport (Cunningham et al., 1997; Drubin and 
Kirschner, 1986; Flanagan et al., 1997; Jenkins and Johnson, 1998; Mandelkow and 
Mandelkow, 1998).  Unpublished work from Grégoire Morisse in the laboratory of Dr. Nicole 
Leclerc (Université de Montréal) has recently shown that Tau proteins interact with Rab5a, 
suggesting that they could be Rab5GAP proteins.  In order to test this possibility, our lab was 
sent samples of purified Tau proteins.  There were three proteins that were tested:  wild type 
Tau, TauR379A, and TauR349A.  The two R/A mutants of Tau were chosen in hopes of 
discovering which, if either, of the two mutated arginine residues were the catalytic ‗arginine 
finger‘ typical of GAP proteins. 
Though the proteins provided by Grégoire Morisse contained impurities (Fig. 4.12A), 
they were sufficiently pure to perform basic GAP assays as per our standard procedure in order 
to determine if they functioned as Rab5GAPs.  Due to the limited quantities and relatively low 
concentrations of the Tau proteins, a titration of 0 µM to 10 µM was chosen for these studies.  
When assayed, all of the Tau proteins showed Rab5GAP activity, and the two mutants showed 
similar or higher Rab5GAP activities as compared to the wild type Tau protein (Fig. 4.12B and 
C).  This suggested that the two arginines chosen for mutation were not the catalytic ‗arginine 
finger‘ residue. 
 
4.4.4 p85 GAP Activity Towards Other Rab Proteins 
Previous data generated from our lab has shown that p85 has GAP activity towards 
other Rab proteins (Chamberlain et al., 2004).  Additional unpublished  data indicated that p85 
has the greater GAP activity towards Rab7 compared to Rab5, with equivalent GAP activity 
towards Rab4 as Rab5 (Chamberlain, 2007).  Also observed was that p85 appeared to have 
little or no GAP activity towards Rab11.  As such, Rab4 and Rab11 were chosen to serve as 
positive and negative controls for p85 GAP assays. 
 When these control assays were performed, however, it was observed that p85 showed 
strong GAP activity towards Rab11.  Because of this, GAP assays analyzing the effects of p85 
on  the  GTP  hydrolysis  activity  of  Rab5 were repeated.  These assays  showed that  p85  had  
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Figure 4.12 – Comparison of Rab5GAP activity of wild type Tau, TauR379A, and 
TauR349A.  Tau proteins were analyzed using the standard GAP assay procedure except that 
100 nM Rab5 was used and the titration was 0 to 10 µM Tau instead of 0 to 32 µM used for 
p85 proteins.  A) Tau proteins were resolved by 12% SDS-PAGE and stained with Coomassie 
Blue. B) Tau proteins were analyzed by GAP assay and visualized as per the standard 
procedure.  Values shown represent the mean +/- standard deviation from three independent 
experiments.  C) The GTP hydrolysis at 6 µM Tau for all three Tau proteins was normalized to 
the % GTP hydrolysed by 100 nM Rab5 alone, with that value being 1.  Values shown 
represent the mean +/- standard deviation for three independent experiments. 
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relatively equivalent GAP activity towards Rab4, 7, and 11 which was somewhat lower than its 
Rab5GAP activity (Fig. 4.13).  It should be noted, however, that these assays were done during 
the period where p85 preparations were displaying Rab5-independent GTP hydrolysis.   The 
GAP activity of p85 towards Rab11 was higher than this background activity, indicating that 
the observed differences from previous data were not simply due to contaminants in the p85 
samples. 
 
4.5 p85:Rab5 Binding Affinity Measurements Using Surface Plasmon Resonance (SPR)  
 Surface plasmon resonance (SPR) was used to measure the binding affinity of p85 to 
Rab5 in vitro.  Surface plasmons are an optical phenomenon arising in thin metal films under 
conditions of total internal reflection.  When light hits the metal surface, much of it reflects and 
is detected, but some of it is absorbed to form surface plasmons.  By increasing the mass on the 
chip, it alters the amount of light that is absorbed, altering the resonance angle.  This produces a 
sharp dip in the intensity of the reflected light at the resonant angle.   The resonant angle itself 
is determined by many factors, including the refractive index of the medium, which itself is 
directly linked to the concentration of dissolved material in that medium.  Using this 
information, it is possible to measure binding to the sensor chip surface.  SPR analysis 
functions by having one protein, the bait protein, immobilized on a sensor chip.  Over this is 
flowed another protein solution, known as the ligand protein.  The binding affinity can be 
directly measured by a small change in the resonance angle due to the change in mass caused 
by the binding of the ligand protein to the bait protein (Fig. 1.8). 
 Rab5 was immobilized covalently by amine coupling onto a CM5 sensor chip to a 
density of approximately 3,000 RU (representing either resonance units or response units, and 
corresponding to a concentration of approximately 3 ng/mm
2
).  The Rab5 was pre-treated with 
10 mM EDTA in an effort to remove any free or weakly associated Mg
2+
 in the Rab5 sample 
prior to immobilization and to remove bound nucleotide.  Depending on the conditions of the 
experiment, nucleotide (GDP or a non-hydrolysable GTP analog) and Mg
2+
 were added to the 
running buffer.  Mg
2+
 was added since Rab5 requires Mg
2+
 in order to bind to a nucleotide, 
while the nucleotides were added to analyze their effect on the Rab5:p85 binding.  Initial 
experiments were done with an Mg
2+ 
concentration of 20 mM and nucleotide concentrations of  
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Figure 4.13 – Comparison of p85 RabGAP activity towards Rab4, Rab5, Rab7, and 
Rab11. Using the standard GAP assay procedure different Rab proteins were assayed for GTP 
hydrolysis at concentrations of 400 nM in the presence of increasing concentrations of p85. A) 
Shown is the p85 RabGAP assay data generated previously in our lab for the following 
proteins: Rab5 (circles), Rab4 (squares), Rab6 (triangles), Rab7 (inverted triangles), Rab11 
(diamonds), no Rab (closed circles) (Chamberlain et al., 2004). B) GAP assay results for p85 
was reanalyzed for the following proteins: Rab5 (filled squares), Rab4 (open diamonds), Rab7 
(triangles), Rab11 (open circles), and no Rab (open triangles). Both graphs (A) and (B) show 
the mean +/- standard deviation for three independent experiments. C) Purified Rab4, 11, and 7 
proteins from (B) were resolved using 15% SDS-PAGE and stained with Coomassie Blue stain 
to analyze purity.  For reference on average p85 and Rab5 protein purity, refer to Fig. 4.1.  
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200 µM based on previous p85:Rab5 interaction assays such as the GAP assay (Anderson and 
Chamberlain, 2005).   
Once Rab5 was immobilized and loaded with the desired cofactor, varying 
concentrations of p85 protein were flowed over the chip at a flow rate of 20 µL/min.  The 
signal (ΔRU = Rab5 flowcell 2 – control flowcell 1) for each concentration of p85 was 
determined and graphed.  Sample binding data for Rab5-GDP + p85 is shown (Fig. 4.14).  
When the ligand (p85) binds to the bait (Rab5) there is a sharp increase in the RU.  The steeper 
the initial change in RU corresponds to the faster the on-rate of binding between the two 
binding partners.  Following initial binding, the signal will begin to plateau, representing that 
the chip is reaching saturating conditions.  At lower concentrations, the initial ΔRU is not as 
steep as there is less ligand to bind, while at higher ligand concentrations the peak plateau 
much earlier.  The concentrations used in this experiment were chosen based on previously 
observed p85 titrations with respect to Rab5 (Chamberlain et al., 2004), and confirmed prior to 
binding studies. 
Experiments were carried out with Rab5 in its three nucleotide-bound states: Rab5-NF, 
Rab5-GDP, and Rab5-GTP.  Using these initial conditions, the binding affinities of the three 
nucleotide-binding states were determined, with p85:Rab5-NF had a KD of 1.9 μM, while the 
KD of the p85:Rab5-GDP and p85:Rab5-GTPγS (a non-hydrolysable GTP analog) were both 
1.5 μM.  While these affinity constants appear quite similar, it should be noted that the 
maximum binding for p85 to Rab5-NF was only approximately 25% compared with p85 
binding to Rab5 in one of its nucleotide-bound states, which appeared to be much the same 
(Fig. 4.15A).  This is likely due to the presence of nucleotides (likely GDP) on the ostensibly 
nucleotide-free Rab5-NF.  If there is nucleotide still on some of the Rab5 immobilized to the 
chip, similar binding affinities will be observed, but lower total binding. 
 It was observed that following each of the binding study injections, there was a steady 
increase of the baseline signal.  This signal proved very difficult to remove with any treatment 
that would not denature the Rab5 immobilized onto the sensor chip.  As p85 is known to 
associate tightly with many of its ligands, it was determined that this accumulation of signal 
represented non-specific interaction between the p85 protein and the sensor chip.  In an effort 
to minimize this non-specific interaction, some changes were made in the composition of the 
buffer  to  optimize results.   The resultant  running  buffer contained  0.5 mM Mg
2+  
(originally 
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Figure 4.14 – Sensorgrams of p85 binding to immobilized Rab5. EDTA-treated Rab5 protein 
was immobilized onto a CM5 sensor chip to approximately 3000 RU of signal on Flowcell 2 (Fc2).  
Flowcell 1 (Fc1) was left clear of immobilized protein to act as a control. Nucleotide, if desired, 
was then added.  Varying concentrations of p85 were then flowed over the chip at a flowrate of 20 
µL/min for 120 seconds.  A) The change in Fc1 and Fc2 signals for the injection 0.96 µM p85.  B) 
The change in Fc1 and Fc2 signals for the injection of 61.44 µM p85.  C) The change in Fc1 signal 
was subtracted from the change in Fc2 signal, producing the net (Fc2-Fc1) signal for a typical 
binding experiment for Rab5-GDP and p85.   
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Figure 4.15 – Binding affinity of p85:Rab5 in different nucleotide binding states. The 
binding peaks at 110 seconds into the 120 second injection were measured and plotted vs. 
concentration of p85 using the same CM5 chip for each replication.  A) The binding peaks 
from three separate binding series on the same sensor chip were converted into % theoretical 
saturation of the Rab5 immobilized chip and plotted against p85 concentration for binding of 
p85 to Rab5-NF (nucleotide free), Rab5-GDP, and Rab5-GTPγS.  Values shown are the mean 
+/- standard deviation for three separate binding experiments.  B) Additional experiments were 
performed following optimization of the BIAcore Running Buffer (50 mM HEPES, pH 8.0, 
150 mM NaCl) to include 0.5 mM Mg2+ and 150 μM nucleotide, as well as the substitution of 
GTPγS for GppCp.  Binding experiments were otherwise performed as per earlier binding 
studies. Values shown are the mean +/- standard deviation for three separate binding 
experiments.  
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10 mM) and 150 μM nucleotide (from 100 µM).  Using this buffer, the KD of p85 to Rab5-GDP 
was 2.2 μM while the KD of p85 to Rab5-GppCp (another non-hydrolysable GTP-analog) was 
1.1 μM (Fig. 4.15B).  Unlike the previous conditions with the non-optimized buffer, the 
maximum binding in the presence of GDP was only 60% of that observed in the presence of 
GppCp. 
 
4.6 p110 Expression Studies 
 p110, the catalytic subunit of PI3K, forms the heterodimeric complex with p85 and may 
have a role in the binding of p85 and Rab5 and help stabilize the switch regions of Rab5.  In 
order to analyze the role that p110 plays in p85:Rab5 binding as well as assay for possible 
p110-encoded Rab5GAP activity, p110 must be produced independently from p85.  Many 
attempts have been made over the years to produce soluble p110 independent of p85, but they 
have not been successful.  It appears that p85 is absolutely required for the stability of p110 
(Yu et al., 1998), and even the coexpression of p85 with p110 generally yields only low levels 
of functional, soluble p110 protein (unpublished data). 
 Attempts to express p110 as a GST-fusion protein in BL21 cells yielded little to no 
detectable p110 in solution or bound to glutathione Sepharose beads.  However, analysis of the 
insoluble pellet following BL21 cell lysis did detect p110, likely in inclusion bodies.  Attempts 
were made to resolublize stable, functional GST-p110 from the insoluble pellets after 
resolublization using a urea cracking buffer, as well as Sarkosyl sulfate using the method 
devised by Tao et al. (Tao et al., 2010).  Unfortunately, none of the proteins resolubilized 
through these methods appeared to renature properly as shown by their inability to bind to 
glutathione Sepharose beads.   
It was theorized that the proteins simply were adopting an improper conformation when 
resolublized using these methods.  To analyze this, a comparison of ‗fast‘ and ‗slow‘ 
renaturation was performed.  The ‗fast‘ renaturation consisted of having the resuspended 
proteins immediately diluted 1:5 into PreScission buffer and then buffer-exchanged to remove 
all the denaturant. The ‗slow‘ technique, conversely, involved a more gradual dilution over 20 
minutes to the same 1:5, followed by buffer-exchanging to remove the denaturants.  
Unfortunately, neither of these techniques yielded recoverable protein (Fig. 4.16).   
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Figure 4.16 - Renaturation of GST-p110. A) The insoluble pellets from the GST-p110 
purification were solublized using Urea-SDS cracking buffer (0.1 M Sodium phosphate 
monobasic, 1%(v/v) -mercaptoethanol, 1% (w/v) SDS, 6 M urea).  These samples were 
immediately diluted 1:5 with PreScission buffer (fast renaturation) and buffer exchanged.  
Alternatively, samples were diluted 1:5 over the course of 20 minutes (slow renaturation) prior 
to being buffer exchanged. The resultant supernatant was incubated for 60 minutes at 4 C with 
glutathione Sepharose beads.  Samples of the glutathione Sepharose resin were resolved using a 
10% SDS-PAGE gel and visualized with Coomassie Blue stain.  B) Glutathione Sepharose 
resin from (A) were then washed three times with standard PreScission buffer and again loaded 
on a 10% SDS-PAGE gel and visualized with Coomassie stain to determine of any of the 
resolubilized could be recovered.  
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In an effort to obtain soluble portions of p110 capable of binding to p85 and/or Rab5, 
fragments of both the  and  isoforms of p110 containing a His6 tag were produced by Dielle 
Detillieux. Four such clones were generated:  p110  and p110  containing the ABD and RBD 
(p110  1-293 and p110  1-291) as well as p110 - and p110 -containing only the ABD and 
RBD as well as the C2 domain, also known to contact p85 (p110  1-503 and p110  1-509). Of 
these fragments, only the p110  1-291 fragment showed any detectable expression (Fig. 4.17).   
However, attempts to further purify this protein were difficult due to an unforeseen issue in 
removing the protein from the TALON affinity resin despite increasing imidazole levels and 
altering the pH (Fig. 4.18).  Thus, experiments to determine the impact of p110 binding on 
p85:Rab5 GAP activity or binding affinities were not possible. 
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Figure 4.17 - Expression of His6-p110 fragments. Several cell lines of either TOP10 or 
M15pREP strains of E. coli which had been transformed to express constructs of p110 were 
grown, induced with IPTG, and lysed with distilled water and SDS sample buffer.  A) 
Schematic of the p110 fragments studied.  Fragments used were derived from both p110   and 
p110 .  All fragments included the p85-binding (ABD) and Ras-binding (RBD) domains, while 
two of the four also included the p110 C2 domain.  B) Whole cell lysates were resolved using 
SDS-PAGE and visualized with Coomassie Blue stain.  C) Whole cell lysates were resolved 
using SDS-PAGE and analyzed by Western blot with anti-His6 tag antibodies to detect the 
His6-p110 proteins. 
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Figure 4.18 – His6-p110  (1-291) has strong binding to TALON resin. p110  1-291 was 
induced as per the standard protein induction and purification procedure for His6-tagged 
proteins (3.2.4).  Following collection of low quantities of solublized protein following 
bacterial lysis, the pellet was resolubilized using Sarkosyl sulfate.  Resolubilized protein was 
recovered from solution using TALON resin.  Two separate imidazole concentrations at two 
separate pHs were attempted to remove the resolubilized protein.  Samples were resolved using 
15% SDS-PAGE and analyzed by Western blot analysis against the His6 tag. 
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5.0 Discussion 
 Previous studies performed in this laboratory have shown that p85 binds to Rab5, as 
well as acting as a Rab5GAP protein, a protein which stimulates the intrinsic GTP hydrolysis 
activity of Rab5 (Anderson and Chamberlain, 2005; Chamberlain and Anderson, 2005; 
Chamberlain et al., 2004; Chamberlain et al., 2008).  However, while previous data have 
shown that these proteins do interact, the precise mechanism of interaction is still not well 
understood.  The goal of this project was to measure the binding affinity of these two proteins, 
as well as to determine if the presence of activated PDGFR influences the binding affinity of 
p85 and Rab5 and/or the Rab5GAP activity of p85. 
 
5.1 Interaction of Rab5 and p85 
 The interaction of the Rab5 and p85 proteins was analyzed using two different methods: 
SPR analysis to directly measure the binding affinity of p85 to Rab5 in different nucleotide-
bound states, and GAP assays to analyze the effect that p85 has on Rab5 GTP hydrolysis. 
 
5.1.1 Binding affinity of p85 to Rab5 
 In order to measure the binding affinities of p85 to Rab5 in different nucleotide bound 
states, Rab5 proteins were immobilized by amine coupling onto a BIAcore™ CM5 Sensor chip 
loaded with or without nucleotides.  The immobilized Rab5 proteins were exposed to purified 
p85 samples which were flowed over the Rab5-immobilized flowcells at increasing 
concentrations.  The net change of signal (measured in RU) was measured and converted into 
total theoretical saturation of the chip assuming 1:1 binding between the p85 and the Rab5 
molecules.  Maximum binding was plotted versus p85 concentration and non-linear regression 
curve fitting allowed binding affinities to be determined. 
 The data that was generated indicates that p85 has a binding affinity towards Rab5 
between 1.1 and 2.2 μM with very little variation observed between the three Rab5 nucleotide-
binding states:  Rab5-NF, Rab5-GDP, and Rab5-GTP.  However, while there was very little 
difference in the binding affinities, there were significant differences in the magnitude of 
binding of p85 to Rab5 in the three nucleotide binding states (Fig. 4.14).  In all experiments, 
p85 showed the greatest total binding to Rab5 bound to the GTP analog GppCp, and the least 
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with Rab5-NF.  However, there was a difference in total magnitude of binding between p85 
binding to Rab5 associated with the GTP analogs GTPγS and GppCp.   
Rab5-GDP appears to bind p85 with equal affinity as it does to Rab5-GTPγS, but not to 
Rab5-GppCp. It can be explained that the similarity between binding of p85 to Rab5-GDP and 
Rab5-GTPγS is due to the hydrolysis of the Rab5-GTPγS into GDP by Rab5, while GppCp 
cannot be hydrolyzed at all.  This is due to the fact that the structure of GppCp contains a 
diester bond between the β and γ phosphate groups instead of the typical phosphate bond in 
GTP, preventing the hydrolysis of the nucleotide.  Conversely, GTPγS contains a sulfur atom in 
place of the double-bonded oxygen atom on the γ-phosphate of GTP which reduces the rate of 
hydrolysis of the nucleotide.  As GTPγS contains the same phosphoester bond as GTP it is 
easier to hydrolyze than GppCp, though it is hydrolyzed three orders of magnitude slower than 
GTP (Karim and Thompson, 1986). 
 When doing these experiments, it was presumed that all nucleotides were removed from 
the purified Rab5 by treating the protein with EDTA to remove its bound Mg
2+
, and with it the 
associated nucleotide.  It was later discovered after performing spectrophotometric analysis of 
the purified Rab5 samples that it was very difficult to remove bound nucleotide (likely GDP 
due to the GTPase activity of Rab5) from the Rab5 proteins.  As such, the fraction of Rab5 that 
was nucleotide free or loaded with one of the GTP analogs (GTPγS and GppCp) was likely 
much less than originally believed.  With the Rab5 proteins being persistently nucleotide-
associated, it is entirely possible that the similarity of the binding affinities of p85 to Rab5 in all 
three nucleotide-bound conformations assayed was caused by the fact that approximately half 
of the Rab5 molecules retained a bound nucleotide (most likely GDP), even in samples treated 
to generate nucleotide-free and GTPγS- or GppCp-bound Rab5.  It is possible that p85 does not 
associate with Rab5-NF and that the binding observed was simply a result of the presence of 
Rab5-GDP.  However, it should be noted that the data does clearly indicate that p85 does bind 
better to Rab5 proteins which are nucleotide-associated and less well once the nucleotide has 
been removed from the Rab5. 
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5.2 p85 as a Rab5GAP 
 Previous studies performed by our lab have shown that p85 is a Rab5GAP 
(Chamberlain et al., 2004) using an assay developed in our lab (Anderson and Chamberlain, 
2005).  In order to analyze the effects of the activated PDGFR on the Rab5GAP activity of p85, 
these experiments were repeated.  Early assays yielded results that were similar to those 
previously reported (Chamberlain et al., 2004) with GTP hydrolysis increased by 570- to 1700-
fold upon p85 addition.  However, as additional assays were performed it was noticed that there 
was increasing variation between the results of the assays.  After performing several control 
experiments it was discovered that the p85 samples were hydrolyzing GTP in the absence of 
Rab5.  Since p85 has been previously shown not to have any GTP hydrolysis activity 
(Chamberlain et al., 2004), this implies that this hydrolysis activity is due to some form of 
contamination in the purified p85 samples.  It was also observed, as stated above (Section 
5.1.1) that Rab5 was detected to be at least partially loaded with nucleotide prior to its loading 
with [ -
32
P]GTP in the GAP assay.  This would prevent the loading of the radiolabelled 
nucleotide into the Rab5 active site, thereby preventing the hydrolysis of GTP to GDP and 
lowering the observed overall activity of both Rab5 and the Rab5GAP activity of p85.   
 
5.2.1 Influence of the PDGFR on p85 Rab5GAP Activity 
 PI3K is recruited to the plasma membrane by the activated, phosphorylated PDGFR 
where it phosphorylates phosphoinositol lipids.  Following receptor internalization, PI3K 
remains associated with the active PDGFR so long as it retains tyrosine phosphorylated sites  
(Ogiso et al., 2002; Pawson and Scott, 2005; Schlessinger, 2000).  As such, there is a period of 
time when p85 would be both PDGFR- and Rab5-associated when the endocytic vesicle is 
tethered to the early/sorting endosome. It has been observed that p85 undergoes a 
conformational change in its N-terminal SH2 domain when PDGFR-associated (Piccione et al., 
1993; Shoelson et al., 1993). It was theorized that this observed conformational change may 
alter the Rab5GAP activity or binding affinity of p85 to Rab5. 
 To analyze the effects that the PDGFR had on p85:Rab5 dynamics, a synthetic peptide 
corresponding to the p85 binding site in both the inactive and active forms of the PDGFR were 
introduced into the GAP assays to measure their effects on p85 Rab5GAP activity.  Similar 
peptides have been shown to elicit the same conformational change in p85 observed when it 
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binds to wild type phosphorylated PDGFR (Panayotou et al., 1992; Shoelson et al., 1993).  It 
was verified that the phosphopeptide (ppPDGFR peptide), but not the non-phosphorylated 
peptide (PDGFR peptide) used did indeed compete with the wild type tyrosine phosphorylated 
PDGFR for p85 binding in vitro. 
 Neither of the PDGFR peptides altered the p85 Rab5GAP activity when added to the 
GAP assay.  This is likely due to the fact that the observed conformational change is primarily 
in the N-terminal SH2 domain rather than the BH domain of p85 which is where the catalytic 
arginine finger important for p85 Rab5GAP activity is located.  These results suggest that 
PDGFR-association and dissociation does not influence the p85 Rab5GAP activity. 
 
5.2.2 p85 GAP Activity toward Rab4, Rab7, and Rab11 
 There are more than 60 human Rab proteins which have been identified, each of which 
has a separate function in relation to the trafficking of endosomes and vesicles in the cell (Barr 
and Lambright, 2010; Pereira-Leal and Seabra, 2000; Seabra and Wasmeier, 2004; Stenmark 
and Olkkonen, 2001).  Previous experiments have shown that p85 has greater GAP activity 
towards Rab7 (Chamberlain, 2007) and equivalent GAP activity to Rab4 as Rab5.  Also 
observed is that p85 appears to have little to no GAP activity towards Rab11 (Chamberlain et 
al., 2004). 
 The GAP activity of p85 was assayed towards Rab4, Rab7, and Rab11 to verify the 
previous results and to explore the possibility of using these proteins as positive and negative 
controls of p85 RabGAP activity.  The resulting data, however, did not match the previous 
reported activity of p85 towards Rab11 with p85 having positive activity towards all of Rab4, 
Rab7, and Rab11.  It was observed that p85 had lower GAP activity towards these three Rab 
proteins than observed towards Rab5.  The reason for this divergent result of p85 towards 
Rab11 is not clear. 
 As with previously mentioned GAP assays, it was later noted that p85 samples 
displayed GTPase activity even in the absence of a Rab GTPase protein.  While the GTP 
hydrolysis observed was much lower than that seen in the presence of Rab protein, this 
hydrolysis activity in the purified p85 preparations may be the cause of the discrepancy 
between the previously reported Rab11 data and the data reported in this study.  This, however, 
is likely not the sole cause of the discrepancy as previous studies (Dielle Detillieux, 
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unpublished data) have shown that Rab11 does not bind p85 while this study showed GTP 
hydrolysis on par with that of Rab4 and Rab7, both of which have been reported to interact 
with p85.  Not only that, but all three proteins (in the presence of p85) showed much greater 
GTP hydrolysis compared to p85 alone, suggesting that the Rab proteins were in fact 
contributing to the GTP hydrolysis activity. 
 
5.3 Tau as a Rab5GAP 
 Tau proteins are microtubule-associated proteins which are involved in the stabilization 
of cytoskeleton in neuronal cells (Bhat and Setaluri, 2007; Lewis et al., 1988).  There are six 
principle Tau isoforms which result from alternate mRNA splicing.  Previous work in the lab of 
Dr. Nicole Leclerc at the Université de Montréal has shown that Tau proteins, specifically the 
383 amino acid Tau4 isoform without the large Tau insert,  was observed to associate with 
Rab5 and appeared to act as a Rab5GAP (Jenny Oberg, unpublished data).  In an effort to 
identify the catalytic arginine finger which is common in many GAPs, a pair of mutants—
TauR379A, and TauR349A—were generated.  These, along with wild type Tau were assayed 
for GAP activity to identify if either of the two arginine residues that were mutated were the 
catalytically important arginine finger. 
When assayed, it was found that neither of the two arginine mutants decreased the GAP 
activity of Tau towards Rab5.  In fact, in both cases the mutant Tau proteins increased the 
relative Rab5GAP activity.  This suggests that not only do the mutated arginines not participate 
in the GAP activity of the Tau protein, but they may even interfere with it.  Further 
mutagenesis experiments are required to identify the catalytic arginine finger within the Tau 
protein and the significance of Rab5 regulation to the biological function of Tau. 
 
5.4 Efforts to Remove Contamination 
 All of the experiments in this study suffered from issues caused by contamination, be it 
nucleotide or protein.  Many different techniques were used to further purify these proteins and 
remove this contamination, most of which met with limited success. 
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5.4.1 Purification of p85 
 It was observed in many experiments that purified p85 preparations exhibited the ability 
to hydrolyse GTP independent of Rab5.  This suggests that there was a contaminating GTPase 
protein which was not removed through purification. 
 
5.4.1.1 Removal of Possible GTPase Contamination From p85 Samples 
 There are many GTPases present in E. coli cells, including the Obg/GTP1 subfamily of 
guanine nucleotide binding proteins.  However, none of the known E. coli GTPases bear a great 
sequence similarity to Rab5, due in part that that bacteria lack the enzymatic machinery to 
prenylate Rab proteins (Elliott et al., 2001; Lei et al., 2000; Pylypenko et al., 2006; Selyunin et 
al., 2011; Shaw et al., 2005; Wout et al., 2004).  This is supported by performing BLAST 
analysis of Rab5 against E. coli proteins.  All of the ones queried had very high E-values (the 
lowest having an E-value of 0.02), implying that there was not a great deal of similarity.  There 
are, however, functional similarities between several proteins, such as the membrane-
trafficking protein ARF6, a member of the Ras superfamily (Elliott et al., 2001; Shaw et al., 
2005).  Because of this it was assumed that one such protein was pulled out along with the p85 
protein. 
The first technique used to increase the purity of the p85 samples involved alteration of 
the standard GST-fusion protein purification procedure.  The first alteration consisted of 
changing the conditions of the lysis buffers used when harvesting the GST-p85 from BL21 
cells.  This, however, did not significantly affect the overall purity of p85.  Increasing the ionic 
strength by more than doubling the concentration of NaCl, changing the detergent used from 
Triton X-100 to NP-40, and adding urea to the buffer did not appear to remove the GTPase 
contamination from p85 purifications.  In addition, analysis of the purified p85 samples by 
Coomassie Blue stain SDS-PAGE gels did not reveal any obvious protein contaminants in any 
of the conditions attempted, including the basic purification procedure.  This suggests that if 
there is a contaminating GTPase, it is present in very low concentrations in the purified p85 
samples. 
Our laboratory has also generated a dual-tagged p85 protein with both an N-terminal 
GST-tag and a C-terminal His6-tag.  This clone was designed to produce ultra-pure samples of 
p85 for purposes such as crystallography. While it was capable of producing ultra-pure p85 
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proteins, when tested in a GAP assay it proved to contain little or no Rab5GAP activity (data 
not shown).  This result suggests that the C-terminal His6-tag, or possibly the additional time 
and manipulations used during the additional purification steps or buffer negatively impacted 
the Rab5GAP activity of p85.  As such, the use of this clone was discontinued for these studies. 
The purified p85 samples were also subjected to anion-exchange chromatography.  This 
process works by separating proteins based on their charges and ability to bind to positively 
charged media.  This technique allows for the separation of proteins based on their relative 
charges at a specific pH.  If there were a contaminating GTPase protein, even if it had the same 
pI as p85, would almost certainly elute off the anion exchange column at a different time than 
p85 due to its different amino acid composition.  However, it was observed that post-anion 
exchange purified p85 showed similar GTP hydrolysis to the non-anion exchange purified p85 
sample.  This suggests that either there is no associated GTPase protein, or that it is bound so 
tightly to p85 that it cannot be removed easily. 
It was observed using dynamic light scattering that p85 in a 50 mM sodium acetate 
buffer, pH 7.0, forms monomers and dimers based on the hydrodynamic radius in solution with 
a Polydispersity of 13.5%  1%.  Polydispersity is a measurement of a sample to indicate the 
presence of multiple populations of different sizes within a sample.  If a sample contains 
multiple populations of different hydrostatic radii it is said to be polydispersed and will have a 
higher Polydispersity.  If the sample contains few individual populations, as represented by 
lower polydispersities the sample is said to be monomodal and has lower observed 
Polydispersity (typically below 20% Polydispersity). Using this information, it should be 
possible to separate out p85 using gel filtration chromatography in a similar buffer.  Once 
isolated, the purified p85 samples could be analyzed using SDS-PAGE and silver staining for 
the presence of small G proteins that could not be identified by Coomassie Blue stain.  
Alternatively, mass spectrometry could be used to analyze the composition of the protein 
samples to analyze if there is a contaminating protein. 
 
5.4.1.2 Possible Degradation of p85 
 Another explanation for the altered activity of p85 is that it was susceptible to 
proteolysis, thereby altering the physical and chemical properties and affinities of the protein.  
Resolving the purified p85 using SDS-PAGE and staining with Coomassie stain revealed in 
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most cases a purified protein band at approximately 83 kDa which corresponds to the size of 
purified p85 protein.  However, it was also observed in many protein batches of p85 that there 
was a smaller quantity of a lower molecular weight protein product around 75 kDa in size 
(Sections 4.2.3).  This smaller protein was resistant to separation from the full-length p85 by 
other means such as anion-exchange chromatography, suggesting that it may be a proteolysed 
form of p85.   
In order to minimize the proteolytic degradation of proteins, all GST-fusion proteins 
were expressed in BL21 cells which lack the Lon protease which degrades abnormal bacterial 
proteins (such as mammalian proteins), and the ompT protease which is normally located in the 
outer membrane (Charette et al., 1981; Dervyn et al., 1990; Gottesman, 1989; Grodberg and 
Dunn, 1988).  Coupled with the fact that the buffers used to lyse the bacteria contained three 
separate protease inhibitors (AEBSF, aprotinin, and leupeptin), proteolysis should be kept to a 
minimum.  It should be noted, however, that the three protease inhibitors used only inhibit 
serine, cysteine, and threonine proteases, while the EDTA present in the bacterial lysis buffer 
which was used both to lyse the cells and store the proteins should inhibit metalloproteases, 
leaving the possibility that aspartate and glutamate proteases may still be present and 
uninhibited.  This is ameliorated, however, by the fact that there are only few aspartate 
proteases that have been identified in prokaryotic systems (Bardy and Jarrell, 2003; LaPointe 
and Taylor, 2000; Ng et al., 2006).   
 
5.4.2 Removal of Bound Nucleotides from Rab5 
 Rab5 is a small monomeric G protein.  Like the similarly functional Ras proteins, there 
is an associated Mg
2+
 ion in its active site which is required for both binding to its cofactor—
GDP or GTP—and for the hydrolysis of GTP into GDP (John et al., 1990; Simon et al., 1996).  
As this Mg
2+
 ion is required for the binding of the nucleotides, it is also theoretically the easiest 
way of removing those nucleotides.  In many experiments it is important to load proteins with 
very specific cofactors or substrates in order to analyze the conformation of that product or its 
physical properties under that conformation.  One of the objectives of this study was to analyze 
the difference in binding affinity of p85 to Rab5 under different nucleotide binding states.  As 
such, a method of removing any residual bound nucleotide from the Rab5 protein and replacing 
it with a different one of our choosing was required. 
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 The original method used for this was simply including 1 mM EDTA in the lysis and 
wash buffers.  EDTA should chelate any metal ions in the solution, removing them and 
hopefully the bound nucleotide as well.  Unfortunately, a spectrophotometric analysis of the 
UV spectrum showed that there was a significant absorption signal at 260 nm compared to 
what was expected for Rab5 proteins.  This high absorption typically indicates the presence of 
contaminating nucleotides (Cavaluzzi and Borer, 2004; Tataurov et al., 2008).  As Rab5 binds 
to both GTP and GDP, it stands to reason that this signal at 260 nm was caused by bound 
guanosine nucleotides.  As such, it was determined that 1 mM EDTA was insufficient to 
remove the associated guanosine nucleotide in the active site.  This observation is supported by 
other studies using Rab5 and the related Rho protein (John et al., 1990).   
Later purifications were performed in 10 mM EDTA, but this also did not appear to 
remove the bound nucleotide to any great degree.  Using a modified version of the technique 
pioneered by John et al., the Rab5 proteins were treated with alkaline phosphatase in the 
presence and absence of snake venom phosphodiesterase (John et al., 1990).  When Rab5 is 
treated with these two enzymes in sequence, all the phosphate groups of the bound guanosine 
nucleotide should be removed, leaving the guanine, or at least a GMP, in its place.  The 
resultant guanine nucleotide should then have a much lower binding affinity to the Rab5 
protein, leading to its removal. 
In all cases where the Rab5 protein itself was not significantly degraded, the trials 
ended with absorbance signals equivalent to the Rab5 samples which were not treated with the 
phosphate-removing enzymes. It is possible that the enzymes did, in fact, act upon the bound 
nucleotides to remove phosphate groups and that the continued signal was due to guanosine 
itself still associated with the protein as it is the nucleotide itself rather than the phosphate 
groups which provides the absorbance at 260 nm.  If this were true, it should make it 
substantially easier to replace the associated nucleotides with the ones desired.  Unfortunately, 
as spectrophotometric analysis is the primary means of detecting the presence of any bound 
nucleotide, it was not possible to measure whether or not these enzymes did in fact have an 
effect on the nature of the Rab5 bound nucleotide (i.e., GMP, GDP, or GTP). 
 Efforts to use ion-exchange chromatography to purify Rab5 also did not meet with 
positive results.   It was also hoped that the nucleotide could be removed using cation-exchange 
chromatography, or alternatively, that the Rab5 proteins themselves could be separated by their 
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nucleotide binding states based on their charge differences.  However, despite many attempts 
using different conditions, Rab5 would not bind to either a cation- or anion-exchange column.  
Because of this, the technique was not used for Rab5 purification. 
It is presently not clear if the failure of the phosphatase/phosphodiesterase treatment 
was due to an inability of the enzymes to hydrolyze the bound nucleotides or if the hydrolyzed 
nucleotides simply exhibited similar affinity towards Rab5 in spite of their fewer phosphate 
groups.  If the failure was in the availability of the phosphate group, a potential analysis would 
be to take aliquots of the purified protein sample and treat them with molybdate/malachite 
green or other phosphate-detection assays (Ekman and Jager, 1993; Harder et al., 1994; 
Maehama et al., 2000; Martin et al., 1985) to track the release of phosphate.  Alternatively, a 
variation of a GAP assay could be performed where instead of measuring the increase in GTP 
hydrolysis with the presence of a GAP protein, you would measure the degradation of 
guanosine nucleotide phosphates using GTP- or GDP-specific antibodies.  This technique, 
however, suffers from the same problem of not being able to replace the Rab5-associated 
nucleotide with an appropriate, radiolabelled nucleotide.  Finally, it is possible to track the 
removal of phosphate and guanine via high-performance liquid chromatography (HPLC) (John 
et al., 1990). 
An additional possibility for removing the associated GDP, or at least replacing it with 
GTP or one of its non-hydrolysable analogs, would be to treat the Rab5 protein with the desired 
nucleotide in the presence of a known GEF protein, such as Rin1 (Chen et al., 2009).  The Rin1 
would theoretically displace any bound GDP with the desired nucleotide (if one other than 
GDP is desired), though it is unknown if GEF proteins would displace GDP for GTP analogs 
such as GppCp or GTPγS as effectively as GTP.  The issue with this is that Rin1 would have to 
be removed from the protein samples, and would need to be expressed as a tagged protein or 
introduced to Rab5 prior to the cleavage of its GST-tag.   
 
5.5 Future Studies 
 In order for these experiments to be continued, more stringent purification procedures 
must be developed.  It has been observed that the p85 protein appears to be associated with 
some sort of contaminating bacterial GTPase, even following multiple purification steps.  One 
way to ameliorate this is to introduce additional purifications steps and to create a new dual-
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tagged p85 protein.  As the presence of the C-terminal His6 tag was linked to ablation of p85 
Rab5GAP activity, the new p85 fusion protein should be N-terminally tagged with His6 and C-
terminally tagged with GST to be cleaved off the fusion protein with a PreScission protease 
enzyme.  With two tags, coupled with anion-exchange chromatography and gel filtration, it 
should be possible to remove any additional associated proteins.  Additionally, purified p85 
samples could be silver stained to better identify contaminating proteins, and those proteins 
could be analyzed by mass spectroscopy to identify if they are p85 degradation products or 
other, non-p85-derived proteins. 
 In terms of removing nucleotide contamination from Rab5 proteins, a more faithful 
repeat of the procedure pioneered by John et al. (John et al., 1990) involving tracking the 
degradation of GTP and GDP via HPLC will probably need to be pursued.  This can be avoided 
in GAP assays if a GST-Rin1 fusion protein can be developed which could be added to the 
Rab5 mastermix in the reaction to replace any associated GDP with [ -
32
P]GTP.  This GST-
Rin1 would be immobilized on glutathione Sepharose resin and removed after a brief (5 
minute) incubation with the Rab5 by centrifugation. However, depending on the binding 
affinity of Rin1 to Rab5 and if it is only a transient association, this procedure may not be 
possible. 
 Following the increased purification procedure, the above studies should be repeated in 
order to ascertain more accurate data.  With decreased nucleotide contaminating the Rab5 
proteins, it will be possible to analyze if p85 does, in fact, associate with Rab5-NF or if the 
previous data to that effect were simply an artefact of the residual nucleotides already bound.  
Additionally, it will give a clearer image of the difference between Rab5:p85 binding in the 
Rab5-GDP and Rab5-GTP binding states. 
 The logical continuation of this study would be to analyze the effect of the activated 
PDGFR, by way of the ppPDGFR peptide, on Rab5:p85 binding.  This can be accomplished 
simply by incubating the p85 samples with 10 to 100 µM of the ppPDGFR peptide.  Though 
the conformational change in the SH2 domain did not alter the GAP activity of p85, it is 
possible that it may influence the ability of the protein to bind to Rab5, or possibly for it to bind 
greater or lesser affinity with different Rab5 nucleotide binding states. 
 The p110 catalytic subunit of PI3K also induces a conformational change when bound 
to p85.  More importantly, it has been shown that the p85 subunit of PI3K has been shown not 
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to stabilize the switch regions of Rab5, one of the primary functions of GAPs (Scheffzek et al., 
1998; Terzyan et al., 2004).  Because p110 is present with p85 when p85 would normally 
interact with Rab5, and p110 can bind selectively to Rab5-GTP, it is theorized that p110 may 
stabilize these switch regions (Christoforidis et al., 1999; McBride et al., 1999; Mills et al., 
1998; Rubino et al., 2000; Simonsen et al., 1998).  Previous attempts to purify p110, either 
separately or coexpressed with p85, have not yielded stable proteins.  However, one possible 
solution to this would be to form a p85-p110 chimeric protein, containing the p85 BH domain, 
N-terminal SH2 domain, and p110 binding domain linked to the p110 protein.  If this chimeric 
protein was stable in solution, it should be able to provide the GAP activity of p85 via the BH 
domain while stabilizing the switch regions though the p110 protein domains (Chamberlain et 
al., 2004). 
 
5.6 Conclusion 
 The objectives of this study were twofold:  To analyze the effects of proteins accessory 
to p85 (specifically the activated PDGFR) on the Rab5GAP activity of p85, and to measure the 
effect that Rab5 nucleotide-binding state has on the binding affinity of p85 towards Rab5.  
While some avenues proved impractical or impossible to pursue, such as the analysis of the role 
of p110 on p85:Rab5 binding and on the Rab5GAP activity of p85, others proved far more 
successful.  It was found that the PDGFR in both its active and inactive conformations did not 
significantly affect the Rab5GAP activity of p85.  It was also found that the mutation of two 
arginines found in Tau, a putative Rab5GAP, to alanines did not confer any reduction in 
observed Rab5GAP activity from Tau.  
For the second objective of this study, it was observed that while p85 binds to Rab5 
with similar affinity regardless of observed Rab5 nucleotide binding state, the total magnitude 
of the two proteins is markedly increased in the presence of a nucleotide.  This was likely due 
to the presence of nucleotide on at least a portion of the immobilized Rab5.  As p85 showed 
noticeable binding to Rab5-GDP p85 may, in addition to its primary role involving p85:Rab5-
GTP binding in p85 Rab5GAP regulation have an additional role in the regulation of Rab5-
GDP, possibly as a Rab5GDF protein.  
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